



## **ESEARCH OPPORTUNITY** ALERTS

Issue 41: Volume 1b



## **GRANTS FROM NATIONAL INSTITUTES OF HEALTH (NIH)**

(January - March, 2022)

A Compilation by the

PRE- & POST AWARD SERVICES OFFICE OF RESEARCH, INNOVATION AND DEVELOPMENT (ORID) UNIVERSITY OF GHANA

January 2022

Research Grants

**Innovation Grants** 

**Academic-Industry Grants** 

**Collaborative Opportunities** 

**Technology Development Grants** 



## TABLE OF CONTENTS

Notice of special interest – T32 complementary and integrative health practitioner supplement programme for pre- and postdoctoral candidates	40
NIH: National Center for Complementary and Integrative Health	40
Closing date: 03 Jan 22	
Notice of special interest – small business initiatives for innovative diagnostitechnology for improving outcomes for maternal health	ic
NIH: National Institute of Biomedical Imaging and Bioengineering	40
Closing date: 05 Jan 22	40
Limited competition – modular budget research project grant for NIH nurse scientist scholars (R01 clinical trial optional): AIDS-related	40
NIH: National Institute of Nursing Research	40
Closing date: 06 Jan 22	40
HIV infection of the central nervous system (R $01$ clinical trial not allowed)	40
NIH: National Institute of Neurological Disorders and Stroke	40
Closing date: 07 Jan 22	41
Dissemination and implementation research in health (R21 clinical trial optional): AIDS-related	41
NIH: National Cancer Institute	41
Closing date: 07 Jan 22	41
Imaging – science track award for research transition (R03 clinical trial optional): AIDS-related	41
NIH: National Institute on Drug Abuse	41
Closing date: 07 Jan 22	41
Small research grant programme (parent R03 clinical trial not allowed): AID related	
NIH: National Human Genome Research Institute	41
Closing date: 07 Jan 22	41
Exploratory or developmental research grant programme (parent R21 clinic trial not allowed): AIDS-related	
NIH: National Eye Institute	42
Closing date: 07 Jan 22	42
NEI research grant for vision related secondary data analysis (R21 clinical tr	ial
NIH: National Eye Institute	42



Closing date: 07 Jan 22	42
Exploratory/developmental bioengineering research grants (R21 clinical tria optional): AIDS-related	
NIH: National Cancer Institute	42
Closing date: 07 Jan 22	42
Bioengineering research grants (R01 clinical trial required): AIDS-related	42
NIH: National Institute of Biomedical Imaging and Bioengineering	42
Closing date: 07 Jan 22	43
Research project grant (parent R01 basic experimental studies with humans required): AIDS-related	43
NIH: National Eye Institute	43
Closing date: 07 Jan 22	43
AIDS-science track award for research transition (R03 clinical trial optional).	43
NIH: National Institute on Drug Abuse	43
Closing date: 07 Jan 22	43
Bioengineering research partnerships (U01 clinical trial required): AIDS-rela	
NIH: National Institute of Biomedical Imaging and Bioengineering	
Closing date: 07 Jan 22	43
National Institute of Dental and Craniofacial Research small grant programme for new investigators (R03 clinical trial not allowed): AIDS-related	
NIH: National Institute of Dental and Craniofacial Research	43
Closing date: 07 Jan 22	44
NLM research grants in biomedical informatics and data science (R01 clinical trial optional): AIDS-related	
NIH: National Library of Medicine	
Closing date: 07 Jan 22	44
Pilot and feasibility studies in preparation for drug and alcohol abuse preventrials (R34 clinical trial optional): AIDS-related	
NIH: National Institute on Drug Abuse	44
Closing date: 07 Jan 22	
Drug discovery for nervous system disorders (R21 clinical trial not allowed): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 07 Jan 22	
Drug discovery for nervous system disorders (R01 clinical trials not allowed) AIDS-related	):
NIH: National Institute of Neurological Disorders and Stroke	45



Closing date: 07 Jan 22	45
EXTENDED DEADLINE: Accelerating the pace of drug abuse research using existing data (R01 clinical trial optional): AIDS-related	45
NIH: National Institute on Drug Abuse	45
Closing date: 07 Jan 22	45
NINDS efficacy clinical trials (UG3/UH3 clinical trial required): AIDS-related	45
NIH: National Institute of Neurological Disorders and Stroke	45
Closing date: 07 Jan 22	45
Discovery of in vivo chemical probes for the nervous system (R01 clinical trial not allowed): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	45
Closing date: 07 Jan 22	46
Development and testing of novel interventions to improve HIV prevention, cand programme implementation (R34 clinical trial optional)	
NIH: National Institute on Drug Abuse	46
Closing date: 07 Jan 22	46
Dissemination and implementation research in health (R01 clinical trial optional): AIDS-related	46
NIH: National Cancer Institute	46
Closing date: 07 Jan 22	46
Dissemination and implementation research in health (R03 clinical trial not allowed): AIDS-related	46
NIH: National Cancer Institute	46
Closing date: 07 Jan 22	46
Sustained release of antivirals for treatment or prevention of HIV (R01 clinica trial not allowed)	
NIH: National Institute of Allergy and Infectious Diseases	47
Closing date: 07 Jan 22	47
New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 clinical trial not allowed): AIDS-related	47
NIH: National Institute of Neurological Disorders and Stroke	47
Closing date: 07 Jan 22	47
Eradication of HIV-1 from central nervous system reservoirs (R01 clinical tria not allowed)	
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 07 Jan 22	
Collaborative clinical vision project – resource centre grant (UG1 clinical trial required): AIDS-related	47



NIH: National Eye Institute	47
Closing date: 07 Jan 224	48
Collaborative clinical vision research – chair's grant (UG1 clinical trial required) AIDS-related	-
NIH: National Eye Institute	48
Closing date: 07 Jan 224	48
Collaborative clinical vision research project – coordinating centre grant (UG1 clinical trial required): AIDS-related	48
NIH: National Eye Institute4	48
Closing date: 07 Jan 224	48
Innovations in HIV testing, adherence and retention to optimise HIV care continuum outcomes (R01 clinical trial optional)	48
NIH: National Institute of Neurological Disorders and Stroke4	48
Closing date: 07 Jan 22	48
End-of-life and palliative needs of adolescents and young adults with serious illnesses (R21 clinical trial optional): AIDS-related	49
NIH: National Institute of Nursing Research	49
Closing date: 07 Jan 224	49
End-of-life and palliative needs of adolescents and young adults with serious illnesses (R01 clinical trial optional): AIDS-related	49
NIH: National Institute of Nursing Research	49
Closing date: 07 Jan 22	49
Small research grants for oral health data analysis and statistical methodology development (R03 clinical trial not allowed): AIDS-related	49
NIH: National Institute of Dental and Craniofacial Research4	49
Closing date: 07 Jan 224	49
Innovations in HIV prevention, testing, adherence and retention to optimise HIV prevention and care continuum outcomes (R21 clinical trial optional)	
NIH: National Institute of Neurological Disorders and Stroke	50
Closing date: 07 Jan 22	50
Extracellular RNA carrier subclasses in processes relevant to substance use disorders or HIV infection (R01 clinical trial not allowed): AIDS-related	50
NIH: National Institute on Drug Abuse	50
Closing date: 07 Jan 22	50
Clinical studies of mental illness (collaborative R01 clinical trial optional): AIDS related	
NIH: National Institute of Neurological Disorders and Stroke	50
Closing date: 07 Jan 22	50



Multidisciplinary studies of HIV/AIDS and ageing (R21 clinical trial optional)	50
NIH: National Institute on Aging	50
Closing date: 07 Jan 22	51
Multidisciplinary studies of HIV/AIDS and ageing (R01 clinical trial optional)	51
NIH: National Institute on Aging	51
Closing date: 07 Jan 22	51
Discovery of cell-based chemical probes for novel brain targets (R21 clinical t not allowed): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	51
Closing date: 07 Jan 22	51
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 clinical trial not allowed): AIDS-related	51
NIH: National Cancer Institute	51
Closing date: 07 Jan 22	51
Understanding and modifying temporal dynamics of coordinated neural activ (R21 clinical trial optional): AIDS-related	•
NIH: National Institute of Neurological Disorders and Stroke	52
Closing date: 07 Jan 22	52
Understanding and modifying temporal dynamics of coordinated neural activ (R01 clinical trial optional): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	52
Closing date: 07 Jan 22	52
Exploratory or developmental research grant programme (parent R21 clinica trial required): AIDS-related	
NIH: National Eye Institute	52
Closing date: 07 Jan 22	52
Joint NINDS/NIMH exploratory neuroscience research grant (R21 clinical tria optional): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	52
Closing date: 07 Jan 22	53
Research project grant (parent R01 clinical trial not allowed): AIDS-related	
NIH: National Eye Institute	53
Closing date: 07 Jan 22	53
Cancer prevention and control clinical trials grant programme (R01 clinical trequired): AIDS-related	
NIH: National Cancer Institute	
Closing date: 07 Jan 22	53



Pilot and feasibility studies of HIV and animal models for HIV infection with mission of the NIDDK (R21 clinical trial not allowed): AIDS-related	
NIH: National Institute of Diabetes and Digestive and Kidney Diseases	
Closing date: 07 Jan 22	
NIDA small research grant programme (R03 clinical trial required): AIDS-r	related
NIH: National Institute on Drug Abuse	
Closing date: 07 Jan 22	
Small research grants for analyses of Gabriella Miller Kids First paediatric research data (R03 clinical trial not allowed): AIDS-related	54
NIH: Eunice Kennedy Shriver National Institute of Child Health and Hum Development	
Closing date: 07 Jan 22	54
Vision research epidemiology grant (UG1 clinical trial not allowed): AIDS-r	
NIH: National Eye Institute	54
Closing date: 07 Jan 22	54
Alcohol and other drug interactions – unintentional injuries and overdoses epidemiology and prevention (R03 clinical trial optional): AIDS-related	
National Institute on Alcohol Abuse and Alcoholism	
Closing date: 07 Jan 22	55
New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 (collab) clinical tri allowed): AIDS-related	ial not
NIH: National Institute of Neurological Disorders and Stroke	55
Closing date: 07 Jan 22	55
Applying a biopsychosocial perspective to self-management of chronic pair clinical trial optional): AIDS-related	
NIH: National Institute of Nursing Research	55
Closing date: 07 Jan 22	55
Biobehavioural basis of chronic pain (R01 clinical trial optional): AIDS-rela	ited.55
NIH: National Institute of Nursing Research	55
Closing date: 07 Jan 22	55
Applying a biopsychosocial perspective to self-management of chronic pair clinical trial optional): AIDS-related	
NIH: National Institute of Nursing Research	56
Closing date: 07 Jan 22	56
Biobehavioural basis of chronic pain (R21 clinical trial optional): AIDS-rela	ited.56
NIH: National Institute of Nursing Research	56



Closing date: 07 Jan 22	56
Fc-dependent mechanisms of antibody-mediated killing (R21 clinical trial not allowed): AIDS-related	
NIH: National Institute of Allergy and Infectious Diseases	56
Closing date: 07 Jan 22	56
Addressing caregiver symptoms through technological tools (R01 clinical trial optional): AIDS-related	
NIH: National Institute of Nursing Research	56
Closing date: 07 Jan 22	57
Addressing caregiver symptoms through technological tools (R21 clinical trial optional): AIDS-related	
NIH: National Institute of Nursing Research	57
Closing date: 07 Jan 22	57
Advancing research in augmentative and alternative communication (R01 clinical trial optional): AIDS-related	57
NIH: National Institute on Deafness and other Communication Disorders	57
Closing date: 07 Jan 22	57
End-of-life and palliative care approaches to advanced signs and symptoms (R clinical trial optional): AIDS-related	
NIH: National Institute of Nursing Research	57
Closing date: 07 Jan 22	57
Advancing research in augmentative and alternative communication (R21 clinical trial optional): AIDS-related	58
NIH: National Institute on Deafness and other Communication Disorders	58
Closing date: 07 Jan 22	58
End-of-life and palliative care approaches to advanced signs and symptoms (R clinical trial optional): AIDS-related	
NIH: National Institute of Nursing Research	58
Closing date: 07 Jan 22	58
Strategies to provide culturally tailored palliative and end-of-life care for seriously ill American Indian and Alaska Native individuals (R01 clinical trial optional): AIDS-related	58
NIH: National Institute of Nursing Research	
Closing date: 07 Jan 22	
Strategies to provide culturally tailored palliative and end-of-life care for	0
seriously ill American Indian and Alaska Native individuals (R21 clinical trial optional): AIDS-related	58
NIH: National Institute of Nursing Research	
Closing date: 07 Jan 22	59



Processing and presentation of non-conventional MHC ligands (R01 clinical tr not allowed): AIDS-related	
NIH: National Institute of Allergy and Infectious Diseases	
Closing date: 07 Jan 22	
Processing and presentation of non-conventional MHC ligands (R21 clinical tr	
NIH: National Institute of Allergy and Infectious Diseases	59
Closing date: 07 Jan 22	59
Telomeres in wellness and disease – a biobehavioural approach (R01 clinical trial optional): AIDS-related	59
NIH: National Institute of Nursing Research	59
Closing date: 07 Jan 22	60
Telomeres in wellness and disease – a biobehavioural approach (R21 clinical trial optional): AIDS-related	60
NIH: National Institute of Nursing Research	60
Closing date: 07 Jan 22	60
Exploratory or developmental research grant programme (parent R21 basic experimental studies with humans required): AIDS-related	60
NIH: National Eye Institute	60
Closing date: 07 Jan 22	60
Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis and other select endemic fungal infections (R01 clinical trnot allowed): AIDS-related	
NIH: National Institute of Allergy and Infectious Diseases	
Closing date: 07 Jan 22	
Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis and other select endemic fungal infections (R21 clinical trnot allowed): AIDS-related	
NIH: National Institute of Allergy and Infectious Diseases	61
Closing date: 07 Jan 22	61
Bioengineering research grants (R01 clinical trial not allowed): AIDS-related	61
NIH: National Institute of Biomedical Imaging and Bioengineering	61
Closing date: 07 Jan 22	61
Bioengineering research partnerships (U01 clinical trial not allowed): AIDS-related	61
NIH: National Institute of Biomedical Imaging and Bioengineering	61
Closing date: 07 Jan 22	61
Exploratory/developmental bioengineering research grants (R21 clinical trial not allowed): AIDS-related	l 61



NIH: National Cancer Institute	61
Closing date: 07 Jan 22	62
EXTENDED DEADLINE: Accelerating the pace of child health research using existing data from the adolescent brain cognitive development study (R21 clinical trial not allowed): AIDS-related	62
NIH: National Institute on Drug Abuse	62
Closing date: 07 Jan 22	62
Comparative effectiveness research in clinical neurosciences (UG3/UH3 clinical not allowed): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	62
Closing date: 07 Jan 22	62
Clinical research study planning grant programme (R34 clinical trial not allowed): AIDS-related	62
NIH: National Eye Institute	62
Closing date: 07 Jan 22	62
Novel RNAs in virology and immune regulation – basic science and therapeut discovery (R21 clinical trial not allowed): AIDS-related	
NIH: National Institute of Allergy and Infectious Diseases	63
Closing date: 07 Jan 22	63
Exploratory clinical neuroscience research on substance use disorders (R61/clinical trial optional): AIDS-related	
NIH: National Institute on Drug Abuse	63
Closing date: 07 Jan 22	63
Mechanisms of tolerance (R21/R33 clinical trial required): AIDS-related	63
National Institute on Alcohol Abuse and Alcoholism	63
Closing date: 07 Jan 22	63
Development and application of PET and SPECT imaging ligands as biomarke for drug discovery and for pathophysiological studies of CNS disorders (R01 clinical trial optional): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 07 Jan 22	
Development and application of PET and SPECT imaging ligands as biomarke for drug discovery and for pathophysiological studies of central nervous syst disorders (R01 clinical trial not allowed): AIDS-related	ers em
NIH: National Institute of Neurological Disorders and Stroke	64
Closing date: 07 Jan 22	64
Catalytic tool and technology development in kidney, urological and haematological diseases (R21 clinical trial not allowed): AIDS-related	64
NIH: National Institute of Diabetes and Digestive and Kidney Diseases	64



Closing date: 07 Jan 22	64
Biomedical data repository (U24 clinical trials not allowed): AIDS-related	64
NIH: National Institute of General Medical Sciences	64
Closing date: 07 Jan 22	64
Biomedical knowledgebase (U24 clinical trials not allowed): AIDS-related	65
NIH: National Institute of General Medical Sciences	65
Closing date: 07 Jan 22	65
Research project grant (parent R01 clinical trial required): AIDS-related	65
NIH: National Eye Institute	65
Closing date: 07 Jan 22	65
HEAL initiative – non-addictive analgesic therapeutics development to treat page (UG3/UH3 clinical trial not allowed): AIDS-related	
NIH: National Institute of Neurological Disorders and Stroke	65
Closing date: 07 Jan 22	
Notice of special interest – telehealth strategies for individuals with HIV and substance use disorders	65
NIH: National Institute on Drug Abuse	65
Closing date: 07 Jan 22	66
Blueprint neurotherapeutics network – biologic-based drug discovery and development for disorders of the nervous system (UG3/UH3 clinical trial optional): AIDS-related	66
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 07 Jan 22	
Notice of special interest – harnessing big data to halt HIV	
NIH: National Institute of Allergy and Infectious Diseases	
Closing date: 07 Jan 22	
Notice of special interest – HIV/AIDS in the era of COVID-19, when pandemics collide	
NIH: National Institute of Allergy and Infectious Diseases	66
Closing date: 07 Jan 22	66
Paediatric immune system – ontogeny and development (R01 clinical trial not allowed): AIDS-related	
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development	67
Closing date: 07 Jan 22	67
Imaging - science track award for research transition (R03 basic experimental studies with humans required): AIDS-related	
NIH: National Institute on Drug Abuse	67



Closing date: 07 Jan 22	.67
Notice of special interest – fundamental and translational research on decision making in ageing and Alzheimer's disease and Alzheimer's disease related dementias	
NIH: National Institute on Aging	
Closing date: 08 Jan 22	
Notice of special interest – bold new engineering research for heart, lung, bloo and sleep disorders and diseases	
NIH: National Heart, Lung and Blood Institute	.68
Closing date: 08 Jan 22	.68
Myeloid-derived suppressor cells as potential therapeutic targets in TB/HIV (R01 clinical trial not allowed)	68
NIH: National Institute of Allergy and Infectious Diseases	68
Closing date: 10 Jan 22	68
Myeloid-derived suppressor cells as potential therapeutic targets in TB/HIV (R21 clinical trial not allowed)	68
NIH: National Institute of Allergy and Infectious Diseases	
Closing date: 10 Jan 22	
Integrating biospecimen science approaches into clinical assay development (U01 clinical trial not allowed)	
NIH: National Cancer Institute	
Closing date: 11 Jan 22	69
NIAID clinical trial planning grant (R34 clinical trial not allowed)	
NIH: National Institute of Allergy and Infectious Diseases	
Closing date: 12 Jan 22	
Programme grants	
Human Frontier Science Program	
Closing date: 13 Jan 22 (Forecast)	
NIAID clinical trial implementation cooperative agreement (U01 clinical trial	
required)	
NIH: National Institute of Allergy and Infectious Diseases	
Closing date: 14 Jan 22	
Single-site investigator-initiated clinical trials (R61/R33 clinical trial required AIDS-related	-
NIH: National Heart, Lung and Blood Institute	.69
Closing date: 14 Jan 22	.70
Systems biology for infectious diseases (U19 clinical trial not allowed)	70
NIH: National Institute of Allergy and Infectious Diseases	70



Closing date: 14 Jan 22	70
Clinical coordinating centre for multi-site investigator-initiated clinical trials (collaborative UG3/UH3 clinical trial required): AIDS-related	70
NIH: National Heart, Lung and Blood Institute	70
Closing date: 14 Jan 22	70
Data coordinating centre for multi-site investigator-initiated clinical trials (collaborative U24 clinical trial required): AIDS-related	70
NIH: National Heart, Lung and Blood Institute	70
Closing date: 14 Jan 22	70
Administrative supplements for research on dietary supplements (admin supplements trial not allowed)	
NIH: National Institutes of Health	71
Closing date: 15 Jan 22	71
Developing digital therapeutics for substance use disorders (UG3/UH3 clinica trial optional): Aids-related	
NIH: National Institute on Drug Abuse	71
Closing date: 17 Jan 22	71
Cellular senescence network – technology development and application in murine systems (UG3/UH3 clinical trial not allowed)	71
NIH: Office of the Director	71
Closing date: 19 Jan 22	71
Collaborative clinical vision project – resource centre grant (UG1 clinical trial required)	71
NIH: National Eye Institute	71
Closing date: 25 Jan 22	72
Collaborative clinical vision research – chair's grant (UG1 clinical trial require	d)
NIH: National Eye Institute	
Closing date: 25 Jan 22	72
Collaborative clinical vision research project – coordinating centre grant (UG1 clinical trial required)	
NIH: National Eye Institute	72
Closing date: 25 Jan 22	72
Genomic community resources (U24 clinical trial not allowed)	72
NIH: National Human Genome Research Institute	72
Closing date: 25 Jan 22	72
Vision research epidemiology grant (UG1 clinical trial not allowed)	73
NIH: National Eye Institute	73



Closing date: 25 Jan 22	.73
Genomic data repositories and knowledgebases	.73
NIH: National Human Genome Research Institute	.73
Closing date: 25 Jan 22	.73
Biomedical knowledgebase (U24 clinical trials not allowed)	
NIH: National Institute of General Medical Sciences	
Closing date: 25 Jan 22	.73
Biomedical data repository (U24 – clinical trials not allowed)	.73
NIH: National Institute of General Medical Sciences	.73
Closing date: 25 Jan 22	
Mechanism-focused research to promote adherence to healthful behaviours to prevent mild cognitive impairment and Alzheimer's disease and related dementias (R01 clinical trial optional)	
NIH: National Institute on Aging	.74
Closing date: 26 Jan 22	.74
Research projects in cancer systems biology (U01 clinical trial optional)	.74
NIH: National Cancer Institute	.74
Closing date: 28 Jan 22	.74
Notice of special interest – administrative supplements for summer research experiences for students and science teachers	.74
NIH: National Institute of Environmental Health Sciences	.74
Closing date: 31 Jan 22	.74
BRAIN initiative – biology and biophysics of neural stimulation and recording technologies (R01 clinical trial optional)	.74
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 01 Feb 22	.75
Pilot projects increasing the impact of the NIH Centres for Advancing Research on Botanicals and Other Natural Products (R03 clinical trials not allowed)	
NIH: National Center for Complementary and Integrative Health	.75
Closing date: 01 Feb 22	.75
Notice of special interest – administrative supplements to support addiction science and related neuroscience pilot research projects at NIMHD-funded research centres in minority institutions	.75
NIH: National Institute on Minority Health and Health Disparities	.75
Closing date: 01 Feb 22	.75
Elucidating the effects of anti-retroviral therapy on neuronal function in the context of substance use dosorders and HIV (R01 clinical trials not allowed)	.75
NIH: National Institute on Drug Abuse	.75



Closing date: 02 Feb 22	76
Role of astrocytes in degeneration of the neurovascular unit in AD/ADRDs (RC clinical trial not allowed)	
NIH: National Institute of Neurological Disorders and Stroke	76
Closing date: 04 Feb 22	76
Dissemination and implementation research in health (R01 clinical trial optional)	
NIH: National Cancer Institute	76
Closing date: 05 Feb 22	76
Bioengineering research grants (R01 clinical trial required)	76
NIH: National Institute of Biomedical Imaging and Bioengineering	76
Closing date: 05 Feb 22	76
Bioengineering research partnerships (U01 clinical trial required)	76
NIH: National Institute of Biomedical Imaging and Bioengineering	76
Closing date: 05 Feb 22	77
Research project grant (parent R01 basic experimental studies with humans required)	77
NIH: National Eye Institute	77
Closing date: 05 Feb 22	77
NLM research grants in biomedical informatics and data science (R01 clinical trial optional)	
NIH: National Library of Medicine	77
Closing date: 05 Feb 22	77
Drug discovery for nervous system disorders (R01 clinical trials not allowed)	77
NIH: National Institute of Neurological Disorders and Stroke	77
Closing date: 05 Feb 22	
EXTENDED DEADLINE: Accelerating the pace of drug abuse research using existing data (R01 clinical trial optional)	77
NIH: National Institute on Drug Abuse	77
Closing date: 05 Feb 22	78
Alzheimer's drug development programme (U01 clinical trial optional)	78
NIH: National Institute on Aging	78
Closing date: 05 Feb 22	78
Research on autism spectrum disorders (R01 clinical trial optional)	78
NIH: National Institute of Mental Health	78
Closing date: 05 Feb 22	78
NINDS exploratory clinical trials (U01 clinical trial required)	78



NIH: National Institute of Neurological Disorders and Stroke	78
Closing date: 05 Feb 22	78
Cellular and molecular biology of complex brain disorders (R01 clinical tri allowed)	
NIH: National Institute of Neurological Disorders and Stroke	79
Closing date: 05 Feb 22	79
NeuroNEXT clinical trials (U01 clinical trial optional)	79
NIH: National Institute of Neurological Disorders and Stroke	79
Closing date: 05 Feb 22	79
Discovery of in vivo chemical probes for the nervous system (R01 clinical t not allowed)	
NIH: National Institute of Neurological Disorders and Stroke	79
Closing date: 05 Feb 22	79
New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 (collab) clinical triallowed)	ial not
NIH: National Institute of Neurological Disorders and Stroke	79
Closing date: 05 Feb 22	80
New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 clinical trial not allowed)	
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 05 Feb 22	
Clinical studies of mental illness (collaborative R01 clinical trial optional).	80
NIH: National Institute of Neurological Disorders and Stroke	80
Closing date: 05 Feb 22	
Research projects to enhance applicability of mammalian models for translational research (R01 clinical trial not allowed)	
NIH: National Cancer Institute	80
Closing date: 05 Feb 22	80
Research on chronic overlapping pain conditions (R01)	80
NIH: National Institute of Neurological Disorders and Stroke	80
Closing date: 05 Feb 22	81
Academic-industrial partnerships for translation of technologies for diagno	osis
and treatment (R01 clinical trial not allowed)	
NIH: National Cancer Institute	81
Closing date: 05 Feb 22	81



Achieving tissue robustness through harnessing immune system plasticity (clinical trial not allowed)	
NIH: National Institute of Dental and Craniofacial Research	
Closing date: 05 Feb 22	81
End-of-life and palliative needs of adolescents and young adults with serious illnesses (R01 clinical trial optional)	S
NIH: National Institute of Nursing Research	81
Closing date: 05 Feb 22	81
Late stage clinical trials for the spectrum of Alzheimer's disease and age-relacognitive decline (R01 clinical trial required)	
NIH: National Institute on Aging	82
Closing date: 05 Feb 22	82
Early-stage clinical trials for the spectrum of Alzheimer's disease and age-re cognitive decline (R01 clinical trial optional)	
NIH: National Institute on Aging	82
Closing date: 05 Feb 22	82
Improving outcomes in cancer treatment-related cardiotoxicity (R01 clinica optional)	
NIH: National Cancer Institute	82
Closing date: 05 Feb 22	82
Development and application of PET and SPECT imaging ligands as biomark for drug discovery and for pathophysiological studies of CNS disorders (R01 clinical trial antique)	L
clinical trial optional)  NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 05 Feb 22	
Programme to assess the rigour and reproducibility of extracellular vesicle-	
derived analytes for cancer detection (R01 clinical trial not allowed)	
NIH: National Cancer Institute	
Closing date: 05 Feb 22	
Translational bioinformatics approaches to advance drug repositioning and combination therapy development for Alzheimer's disease (R01 clinical tria optional)	l
NIH: National Institute on Aging	
Closing date: 05 Feb 22	
Academic-industrial partnerships to translate and validate in vivo cancer	
imaging systems (R01 clinical trial optional)	84
NIH: National Cancer Institute	
Closing date: 05 Feb 22	Q1.



Perception and cognition research to inform cancer image perception (R01 clinical trial optional)	
NIH: National Cancer Institute	
Closing date: 05 Feb 22	
Cancer tissue engineering collaborative – enabling biomimetic tissue-engineerhnologies for cancer research (R01 clinical trial optional)	
NIH: National Cancer Institute	84
Closing date: 05 Feb 22	84
Secondary analysis and integration of existing data to elucidate the genetic architecture of cancer risk and related outcomes (R01 clinical trial not allowed)	wed)
NIH: National Cancer Institute	
Closing date: 05 Feb 22	
Effectiveness trials for post-acute interventions and services to optimise lo term outcomes (R01 clinical trial required)	nger-
NIH: National Institute of Neurological Disorders and Stroke	85
Closing date: 05 Feb 22	
Assay development and screening for discovery of chemical probes, drugs immunomodulators (R01 clinical trial not allowed)	
NIH: National Cancer Institute	85
Closing date: 05 Feb 22	85
Understanding and modifying temporal dynamics of coordinated neural ac (R01 clinical trial optional)	
NIH: National Institute of Neurological Disorders and Stroke	85
Closing date: 05 Feb 22	85
Research project grant (parent R01 clinical trial not allowed)	86
NIH: National Eye Institute	86
Closing date: 05 Feb 22	86
Alzheimer's clinical trials consortium clinical trials (R01 clinical trial requi	red)86
NIH: National Institute on Aging	86
Closing date: 05 Feb 22	86
Cancer prevention and control clinical trials grant programme (R01 clinica required)	
NIH: National Cancer Institute	86
Closing date: 05 Feb 22	86
Investigator-initiated early phase clinical trials for cancer treatment and diagnosis (R01 clinical trial required)	86
NIH: National Cancer Institute	86



Closing date: 05 Feb 22	86
Innovative screening approaches and therapies for screenable disorders in ne borns (R01 clinical trial optional)	
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development	
Closing date: 05 Feb 22	87
Innovative mental health services research not involving clinical trials (R01).	87
NIH: National Institute of Neurological Disorders and Stroke	87
Closing date: 05 Feb 22	87
Investigator-initiated research in computational genomics and data science (linical trial not allowed)	
NIH: National Human Genome Research Institute	87
Closing date: 05 Feb 22	87
Novel mechanism research on neuropsychiatric symptoms in Alzheimer's dementia (R01 clinical trial optional)	88
NIH: National Institute of Neurological Disorders and Stroke	88
Closing date: 05 Feb 22	88
Development and optimisation of tasks and measures for functional domains behaviour (R01 clinical trial not allowed)	
NIH: National Institute of Neurological Disorders and Stroke	88
Closing date: 05 Feb 22	88
Neuromodulation and neurostimulation device development for mental healt applications (R01 clinical trial not allowed)	
NIH: National Institute of Neurological Disorders and Stroke	88
Closing date: 05 Feb 22	88
Biobehavioural basis of chronic pain (R01 clinical trial optional)	88
NIH: National Institute of Nursing Research	88
Closing date: 05 Feb 22	89
Applying a biopsychosocial perspective to self-management of chronic pain (labeled trial optional)	
NIH: National Institute of Nursing Research	89
Closing date: 05 Feb 22	89
Addressing caregiver symptoms through technological tools (R01 clinical tria optional)	
NIH: National Institute of Nursing Research	89
Closing date: 05 Feb 22	89
Basic neurodevelopmental biology of circuits and behaviour (R01 clinical tria not allowed)	



NIH: National Institute of Neurological Disorders and Stroke	89
Closing date: 05 Feb 22	89
Building in vivo preclinical assays of circuit engagement for application in therapeutic development (R01 clinical trial not allowed)	89
NIH: National Institute of Neurological Disorders and Stroke	89
Closing date: 05 Feb 22	90
Advancing research in augmentative and alternative communication (R01 clinical trial optional)	90
NIH: National Institute on Deafness and other Communication Disorders	90
Closing date: 05 Feb 22	90
End-of-life and palliative care approaches to advanced signs and symptoms (R clinical trial optional)	
NIH: National Institute of Nursing Research	90
Closing date: 05 Feb 22	90
Strategies to provide culturally tailored palliative and end-of-life care for seriously ill American Indian and Alaska Native individuals (R01 clinical trial optional)	90
NIH: National Institute of Nursing Research	
Closing date: 05 Feb 22	90
Processing and presentation of non-conventional MHC ligands (R01 clinical transcription)	
NIH: National Institute of Allergy and Infectious Diseases	
Closing date: 05 Feb 22	91
Telomeres in wellness and disease – a biobehavioural approach (R01 clinical trial optional)	91
NIH: National Institute of Nursing Research	91
Closing date: 05 Feb 22	91
Accelerating malaria vaccine discovery (R01 clinical trial not allowed)	91
NIH: National Institute of Allergy and Infectious Diseases	91
Closing date: 05 Feb 22	91
Advancing development of rapid fungal diagnostics (R01 clinical trial not allowed)	91
NIH: National Institute of Allergy and Infectious Diseases	
Closing date: 05 Feb 22	92
Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis and other select endemic fungal infections (R01 clinical translation)	ial
NIH: National Institute of Allergy and Infectious Diseases	
Closing date: 05 Feb 22	92



Molecular and genetic characterisation of inborn errors of immunity (R01 clinical trial not allowed)	92
NIH: National Institute of Allergy and Infectious Diseases	92
Closing date: 05 Feb 22	92
Control of sexually transmitted infections through a comprehensive inderstanding of the natural history of infection (R01 clinical trial not allow	-
NIH: National Institute of Allergy and Infectious Diseases	
Closing date: 05 Feb 22	
Emotion regulation, ageing and mental disorder (R01 clinical trial not allow	
	-
NIH: National Institute of Neurological Disorders and Stroke	93
Closing date: 05 Feb 22	93
Bioengineering research grants (R01 clinical trial not allowed)	93
NIH: National Institute of Biomedical Imaging and Bioengineering	93
Closing date: 05 Feb 22	93
Bioengineering research partnerships (U01 clinical trial not allowed)	93
NIH: National Institute of Biomedical Imaging and Bioengineering	93
Closing date: 05 Feb 22	93
Accelerating the pace of child health research using existing data from the adolescent brain cognitive development study (R01 clinical trial not allowed)	ed)93
NIH: National Institute on Drug Abuse	93
Closing date: 05 Feb 22	93
Biology of bladder cancer (R01 clinical trial optional)	94
NIH: National Cancer Institute	94
Closing date: 05 Feb 22	94
Limited competition – additional sequencing for the Alzheimer's disease sequencing project (U01 clinical trial not allowed)	94
NIH: National Institute on Aging	94
Closing date: 05 Feb 22	94
Cognitive systems analysis of Alzheimer's disease genetic and phenotypic of (U01 clinical trial not allowed)	
NIH: National Institute on Aging	94
Closing date: 05 Feb 22	94
Multisite clinical trial implementation grant (R01 clinical trial required)	94
NIH: National Institute on Aging	94
Closing date: 05 Feb 22	95



mechanism-based interventional strategies (R01 clinical trial optional)	95
NIH: National Cancer Institute	
Closing date: 05 Feb 22	
Utilising invasive recording and stimulating opportunities in humans to advange neural circuitry understanding of mental health disorders (R01 clinical trial optional)	ice
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 05 Feb 22	
Development and application of PET and SPECT imaging ligands as biomarker for drug discovery and for pathophysiological studies of central nervous syste disorders (R01 clinical trial not allowed)	m
NIH: National Institute of Neurological Disorders and Stroke	95
Closing date: 05 Feb 22	95
Transcriptomic, epigenomic, regulatory RNA or functional genomic research is substance use disorders	
NIH: National Institute on Drug Abuse	96
Closing date: 05 Feb 22	96
Research on myalgic encephalomyelitis/chronic fatigue syndrome (R01 clinicatrials not allowed)	
NIH: National Institute of Neurological Disorders and Stroke	96
Closing date: 05 Feb 22	96
Research project grant (parent R01 clinical trial required)	96
NIH: National Eye Institute	96
Closing date: 05 Feb 22	96
Behavioural tasks targeting brain systems relevant to anhedonia (R01 basic experimental studies with humans required)	96
NIH: National Institute of Neurological Disorders and Stroke	96
Closing date: 05 Feb 22	96
Notice of special interest – simulation modelling and systems science to addre health disparities	
NIH: National Institute on Minority Health and Health Disparities	97
Closing date: 05 Feb 22	97
Notice of special interest – palliative care in heart, lung, blood and sleep disease	
NIH: National Heart, Lung and Blood Institute	
Closing date: 05 Feb 22	97
Notice of special interest – the influence of host resilience on heterogeneity of acute respiratory distress syndrome/acute lung injury	97



NIH: National Heart, Lung and Blood Institute	97
Closing date: 05 Feb 22	97
Notice of special interest – integrative omics analysis of NHLBI TOPMed data (parent R01 clinical trial not allowed)	97
NIH: National Heart, Lung and Blood Institute	97
Closing date: 05 Feb 22	98
Mood and psychosis symptoms during the menopause transition (R01 clinical trial optional)	
NIH: National Institute of Neurological Disorders and Stroke	98
Closing date: 05 Feb 22	98
Notice of special interest – advances in research for the treatment, services are recovery of alcohol use disorder	
National Institute on Alcohol Abuse and Alcoholism	98
Closing date: 05 Feb 22	98
Notice of special interest – research to address vaccine hesitancy, uptake and implementation among populations that experience health disparities	
NIH: National Institute on Minority Health and Health Disparities	98
Closing date: 05 Feb 22	98
Notice of special interest – leveraging real-world imaging data for artificial intelligence-based modelling and early detection of abdominal cancers	98
NIH: National Cancer Institute	98
Closing date: 05 Feb 22	99
Natural history of disorders screenable in the newborn period (R01 clinical troptional)	
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development	
Closing date: 05 Feb 22	99
Academic-industrial partnerships for translation of technologies for diagnosis and treatment (R01 - clinical trial optional)	
NIH: National Cancer Institute	99
Closing date: 05 Feb 22	99
Screening and functional validation of human birth defects genomic variants (R01 clinical trial not allowed)	99
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development	
Closing date: 05 Feb 22	100
Dyadic interpersonal processes and biopsychosocial outcomes (R01 clinical trials not allowed)	100
NIH: National Institutes of Health	100



Closing date: 05 Feb 22	100
Paediatric immune system – ontogeny and development (R01 clinical trial nallowed)	
NIH: Eunice Kennedy Shriver National Institute of Child Health and Huma Development	
Closing date: 05 Feb 22	100
Notice of special interest – immune responses to arthropod feeding on vertebrate hosts	100
NIH: National Institute of Allergy and Infectious Diseases	100
Closing date: 05 Feb 22	100
Basic research in cancer health disparities (R01 clinical trial not allowed)	101
NIH: National Cancer Institute	101
Closing date: 05 Feb 22	101
Notice of special interest - somatic cell gene editing therapies to improve transplantation outcomes	101
NIH: National Institute of Allergy and Infectious Diseases	101
Closing date: 05 Feb 22	101
Clinical trial readiness for functional neurological disorders (U01 clinical trial optional)	
NIH: National Institute of Neurological Disorders and Stroke	101
Closing date: 05 Feb 22	101
Modulating human microbiome function to enhance immune responses agai cancer (R01 clinical trial not allowed)	
NIH: National Cancer Institute	101
Closing date: 05 Feb 22	101
Ethical issues in translational science research (R01 clinical trial optional)	102
NIH: National Center for Advancing Translational Sciences	102
Closing date: 08 Feb 22	102
Identification and characterisation of persistence mechanisms of select protozoan pathogens (R01 clinical trial not allowed)	102
NIH: National Institute of Allergy and Infectious Diseases	102
Closing date: 08 Feb 22	102
NINDS efficacy clinical trials (UG3/UH3 clinical trial required)	102
NIH: National Institute of Neurological Disorders and Stroke	102
Closing date: 09 Feb 22	102
Blueprint neurotherapeutics network – small molecule drug discovery and development for disorders of the nervous system (UG3/UH3 clinical trial optional)	102
Up(1011a1	104



NIH: National Institute of Neurological Disorders and Stroke	102
Closing date: 09 Feb 22	103
Blueprint neurotherapeutics network – biologic-based drug discovery and development for disorders of the nervous system (UG3/UH3 clinical trial	102
optional)	
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 09 Feb 22	103
Pharmacokinetics and pharmacodynamics of $\Delta 9$ -tetrahydrocannabinol in cannabis and cannabis products (R01 clinical trial optional)	
NIH: National Institute on Drug Abuse	
Closing date: 09 Feb 22	103
Pharmacokinetics and pharmacodynamics of $\Delta 9$ -tetrahydrocannabinol in cannabis and cannabis products (R21 clinical trial optional)	103
NIH: National Institute on Drug Abuse	103
Closing date: 09 Feb 22	103
Pragmatic trials for dementia care and caregiver support (R61/R33 clinical required)	
NIH: National Institute on Aging	104
Closing date: 10 Feb 22	104
Dementia care and caregiver support intervention research (R01 clinical tr	
NIH: National Institute on Aging	104
Closing date: 10 Feb 22	104
Utilising the PLCO biospecimens resource to bridge gaps in cancer aetiolog early-detection research (U01 clinical trial not allowed)	
NIH: National Cancer Institute	104
Closing date: 11 Feb 22	104
Single-site investigator-initiated clinical trials (R61/R33 clinical trial requi	
NIH: National Heart, Lung and Blood Institute	104
Closing date: 11 Feb 22	105
Clinical coordinating centre for multi-site investigator-initiated clinical tria (collaborative UG3/UH3 clinical trial required)	
NIH: National Heart, Lung and Blood Institute	105
Closing date: 11 Feb 22	105
Data coordinating centre for multi-site investigator-initiated clinical trials (collaborative U24 clinical trial required)	105
NIH: National Heart, Lung and Blood Institute	105
Closing date: 11 Feb 22	105



HIV/AIDS high priority drug abuse research (R01 clinical trial optional)	105
NIH: National Institute on Drug Abuse	105
Closing date: 15 Feb 22	105
Tobacco regulatory science (R01 clinical trial optional)	106
NIH: National Cancer Institute	106
Closing date: 15 Feb 22	106
HEAL initiative – non-addictive analgesic therapeutics development to tre (UG3/UH3 clinical trial not allowed)	_
NIH: National Institute of Neurological Disorders and Stroke	106
Closing date: 15 Feb 22	106
Pilot projects increasing the impact of the NIH Centres for Advancing Rese on Botanicals and Other Natural Products (R03 clinical trials not allowed) related	: AIDS-
NIH: National Center for Complementary and Integrative Health	106
Closing date: 15 Feb 22	106
NEI research grant for vision related secondary data analysis (R21 clinical not allowed)	
NIH: National Eye Institute	106
Closing date: 16 Feb 22	107
Imaging – science track award for research transition (R03 clinical trial op	
NIH: National Institute on Drug Abuse	107
Closing date: 16 Feb 22	107
Exploratory or developmental research grant programme (parent R21 clin trial not allowed)	
NIH: National Eye Institute	107
Closing date: 16 Feb 22	107
Small research grants for oral health data analysis and statistical methodo development (R03 clinical trial not allowed)	
NIH: National Institute of Dental and Craniofacial Research	107
Closing date: 16 Feb 22	107
Dissemination and implementation research in health (R21 clinical trial optional)	108
NIH: National Cancer Institute	108
Closing date: 16 Feb 22	
Small research grant programme (parent R03 clinical trial not allowed)	
NIH: National Institute of Nursing Research	108
Closing date: 16 Feb 22	108



Research on autism spectrum disorders (R03 clinical trial optional)10	)8
NIH: National Institute of Neurological Disorders and Stroke10	)8
Closing date: 16 Feb 2210	)8
Research on autism spectrum disorders (R21 clinical trial optional)10	)8
NIH: National Institute of Neurological Disorders and Stroke10	)8
Closing date: 16 Feb 2210	)8
Exploratory/developmental bioengineering research grants (R21 clinical trial optional)10	)9
NIH: National Cancer Institute10	)9
Closing date: 16 Feb 2210	)9
Drug discovery for nervous system disorders (R21 clinical trial not allowed) $.10$	)9
NIH: National Institute of Neurological Disorders and Stroke10	)9
Closing date: 16 Feb 2210	)9
National Institute of Dental and Craniofacial Research small grant programme for new investigators (R03 clinical trial not allowed)10	)9
NIH: National Institute of Dental and Craniofacial Research10	)9
Closing date: 16 Feb 2210	)9
Pilot and feasibility studies in preparation for drug and alcohol abuse preventio trials (R34 clinical trial optional)	
NIH: National Institute on Drug Abuse10	)9
Closing date: 16 Feb 2211	0
Pilot health services and economic research on the treatment of drug, alcohol and tobacco abuse (R34 clinical trial optional)11	10
NIH: National Institute on Drug Abuse11	
Closing date: 16 Feb 22	
Dissemination and implementation research in health (R03 clinical trial not	.0
allowed)11	0
NIH: National Cancer Institute11	0
Closing date: 16 Feb 2211	0
Research on chronic overlapping pain conditions (R21 clinical trial not allowed)	)
NIH: National Institute of Neurological Disorders and Stroke11	0
Closing date: 16 Feb 2211	0
Achieving tissue robustness through harnessing immune system plasticity (R21 clinical trial not allowed)11	1
NIH: National Institute of Dental and Craniofacial Research11	1
Closing date: 16 Feb 2211	1



allowed)	
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 16 Feb 22	
End-of-life and palliative needs of adolescents and young adults with seri illnesses (R21 clinical trial optional)	ious
NIH: National Institute of Nursing Research	
Closing date: 16 Feb 22	
Clinical trial readiness for rare neurological and neuromuscular diseases clinical trial not allowed)	-
NIH: National Institute of Neurological Disorders and Stroke	111
Closing date: 16 Feb 22	
Improving outcomes in cancer treatment-related cardiotoxicity (R21 clin optional)	ical trial
NIH: National Cancer Institute	112
Closing date: 16 Feb 22	112
Small research grants for analyses of Gabriella Miller Kids First paediatri research data (R03 clinical trial not allowed)	
NIH: Eunice Kennedy Shriver National Institute of Child Health and Hu Development	
Closing date: 16 Feb 22	112
Perception and cognition research to inform cancer image interpretation clinical trial optional)	-
NIH: National Cancer Institute	112
Closing date: 16 Feb 22	112
Secondary analysis and integration of existing data to elucidate the genet architecture of cancer risk and related outcomes (R21 clinical trials not a	llowed)
NIH: National Cancer Institute	113
Closing date: 16 Feb 22	113
Pilot effectiveness trials for post-acute interventions and services to opti longer-term outcomes (R34 clinical trial required)	mise
NIH: National Institute of Neurological Disorders and Stroke	113
Closing date: 16 Feb 22	113
Discovery of cell-based chemical probes for novel brain targets (R21 clin not allowed)	
NIH: National Institute of Mental Health	
Closing date: 16 Feb 22	113



Understanding and modifying temporal dynamics of coordinated neural a (R21 clinical trial optional)	-
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 16 Feb 22	
Exploratory or developmental research grant programme (parent R21 cli	
trial required)	
NIH: National Eye Institute	114
Closing date: 16 Feb 22	114
Joint NINDS/NIMH exploratory neuroscience research grant (R21 clinical optional)	
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 16 Feb 22	
NICHD small grant programme (R03 clinical trial optional)	
NIH: Eunice Kennedy Shriver National Institute of Child Health and Hur Development	nan
Closing date: 16 Feb 22	
Pilot studies of biological, behavioural and social mechanisms contributin HIV pathogenesis within the mission of the NIDDK (R21 clinical trial not	
allowed)	115
NIH: National Institute of Diabetes and Digestive and Kidney Diseases	
Closing date: 16 Feb 22	
NIDA small research grant programme (R03 clinical trial required)	
NIH: National Institute on Drug Abuse	
Closing date: 16 Feb 22	
Mechanisms of alcohol tolerance (R21/R33 clinical trial not allowed)	
National Institute on Alcohol Abuse and Alcoholism	
Closing date: 16 Feb 22	
Innovative screening approaches and therapies for screenable disorders i borns (R03 clinical trial optional)	
NIH: Eunice Kennedy Shriver National Institute of Child Health and Hur Development	
Closing date: 16 Feb 22	116
Innovative screening approaches and therapies for screenable disorders i borns (R21 clinical trial optional)	
NIH: Eunice Kennedy Shriver National Institute of Child Health and Hur Development	
Closing date: 16 Feb 22	116
Small research grants for establishing basic science-clinical collaborations understand structural birth defects (R03 clinical trial not allowed)	



Nih: Eunice Kennedy Shriver National Institute of Child Health and Human Development	16
Closing date: 16 Feb 22	
Investigator-initiated research in computational genomics and data science (R2 clinical trial not allowed)11	21
NIH: National Human Genome Research Institute11	16
Closing date: 16 Feb 2211	17
Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R03 clinical trial optional)	
National Institute on Alcohol Abuse and Alcoholism11	17
Closing date: 16 Feb 2211	17
Novel mechanism research on neuropsychiatric symptoms in Alzheimer's dementia (R21 clinical trial optional)11	17
NIH: National Institute of Neurological Disorders and Stroke11	17
Closing date: 16 Feb 2211	
Applying a biopsychosocial perspective to self-management of chronic pain (R2 clinical trial optional)11	
NIH: National Institute of Nursing Research11	17
Closing date: 16 Feb 2211	17
Biobehavioural basis of chronic pain (R21 clinical trial optional)11	18
NIH: National Institute of Nursing Research11	18
Closing date: 16 Feb 2211	18
Fc-dependent mechanisms of antibody-mediated killing (R21 clinical trial not allowed)11	18
NIH: National Institute of Allergy and Infectious Diseases11	18
Closing date: 16 Feb 2211	18
Addressing caregiver symptoms through technological tools (R21 clinical trial optional)1	18
NIH: National Institute of Nursing Research11	18
Closing date: 16 Feb 2211	18
Basic neurodevelopmental biology of brain circuits and behaviour (R21 clinical trial not allowed)	
NIH: National Institute of Neurological Disorders and Stroke11	18
Closing date: 16 Feb 2211	18
Advancing research in augmentative and alternative communication (R21 clinical trial optional)1	19
NIH: National Institute on Deafness and other Communication Disorders 11	19
Closing date: 16 Feb 2211	19



End-of-life and palliative care approaches to advanced signs and sympto clinical trial optional)	
NIH: National Institute of Nursing Research	
Closing date: 16 Feb 22	
Strategies to provide culturally tailored palliative and end-of-life care for seriously ill American Indian and Alaska Native individuals (R21 clinical optional)	trial
NIH: National Institute of Nursing Research	
Closing date: 16 Feb 22	
Processing and presentation of non-conventional MHC ligands (R21 clini not allowed)	cal trial
NIH: National Institute of Allergy and Infectious Diseases	120
Closing date: 16 Feb 22	120
Telomeres in wellness and disease – a biobehavioural approach (R21 clintrial optional)	
NIH: National Institute of Nursing Research	
Closing date: 16 Feb 22	120
Molecular and genetic characterisation of inborn errors of immunity (R2 clinical trial not allowed)	1 120
NIH: National Institute of Allergy and Infectious Diseases	
Closing date: 16 Feb 22	
Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis and other select endemic fungal infections (R21 clini not allowed)	cal trial
NIH: National Institute of Allergy and Infectious Diseases	120
Closing date: 16 Feb 22	
Advancing development of rapid fungal diagnostics (R21 clinical trial not allowed)	
NIH: National Institute of Allergy and Infectious Diseases	121
Closing date: 16 Feb 22	121
Exploratory or developmental research grant programme (parent R21 be experimental studies with humans required)	
NIH: National Eye Institute	121
Closing date: 16 Feb 22	121
Emotion regulation, ageing and mental disorder (R21 clinical trial not all	_
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 16 Feb 22	



exploratory/developmental bloengineering research grants (R21 clinical trinot allowed)	
NIH: National Cancer Institute	
Closing date: 16 Feb 22	
EXTENDED DEADLINE: Accelerating the pace of child health research using existing data from the adolescent brain cognitive development study (R21 clinical trial not allowed)	
NIH: National Institute on Drug Abuse	
Closing date: 16 Feb 22	
Biology of bladder cancer (R21 clinical trial optional)	122
NIH: National Cancer Institute	
Closing date: 16 Feb 22	122
Clinical research study planning grant programme (R34 clinical trial not allowed)	
NIH: National Eye Institute	
Closing date: 16 Feb 22	
Novel RNAs in virology and immune regulation – basic science and therapeu discovery (R21 clinical trial not allowed)	itic
NIH: National Institute of Allergy and Infectious Diseases	123
Closing date: 16 Feb 22	123
Modulating human microbiome function to enhance immune responses agai cancer (R21 clinical trial not allowed)	
NIH: National Cancer Institute	123
Closing date: 16 Feb 22	123
Mechanisms of tolerance (R21/R33 clinical trial required)	123
National Institute on Alcohol Abuse and Alcoholism	123
Closing date: 16 Feb 22	123
Small research grant programme for the next generation of clinical research in Alzheimer's disease and Alzheimer's disease related dementias research - area of focus archiving and leveraging existing data sets for analyses (R03 clinical trial not allowed)	-
NIH: National Institute on Aging	
Closing date: 16 Feb 22	
Small research grant programme for the next generation of clinical research in AD/ADRD research – area of focus systems biology (R03 clinical trial not allowed)	ers
NIH: National Institute on Aging	
Closing date: 16 Feb 22	124



in AD/ADRD research – area of focus basic science (R03 clinical trials not	ners
allowed)	
NIH: National Institute on Aging	
Closing date: 16 Feb 22	124
Catalytic tool and technology development in kidney, urological and haematological diseases (R21 clinical trial not allowed)	124
NIH: National Institute of Diabetes and Digestive and Kidney Diseases	124
Closing date: 16 Feb 22	124
Research on myalgic encephalomyelitis/chronic fatigue syndrome (R21 clitrials not allowed)	
NIH: National Institute of Neurological Disorders and Stroke	125
Closing date: 16 Feb 22	125
Notice of special interest – small grants for secondary analyses of existing sets and stored biospecimens	
NIH: Eunice Kennedy Shriver National Institute of Child Health and Hum Development	
Closing date: 16 Feb 22	125
Mood and psychosis symptoms during the menopause transition (R21 clin trial optional)	
NIH: National Institute of Neurological Disorders and Stroke	125
Closing date: 16 Feb 22	125
NICHD small research grant programme (R03 basic experimental studies vhumans required)	
NIH: Eunice Kennedy Shriver National Institute of Child Health and Hum Development	
Closing date: 16 Feb 22	126
Notice of special interest – use of digital technology and mobile health to improve diagnosis, assessments, interventions, management and outcome individuals with down syndrome across the lifespan (R21 clinical trial not allowed)	
NIH: National Center for Complementary and Integrative Health	126
Closing date: 16 Feb 22	126
Imaging - science track award for research transition (R03 basic experime studies with humans required)	
NIH: National Institute on Drug Abuse	126
Closing date: 16 Feb 22	
Basic research in cancer health disparities (R03 clinical trial not allowed).	
NIH: National Cancer Institute	
Closing date: 16 Feb 22	



Basic research in cancer health disparities (R21 clinical trial not allowed)	12/
NIH: National Cancer Institute	127
Closing date: 16 Feb 22	127
Regenerative medicine clinical trial planning grant (R34 clinical trials not allowed)	
NIH: National Eye Institute	
Closing date: 16 Feb 22	
Ethical, legal and social implications small research grant (R03 clinical trioptional)	al
NIH: National Human Genome Research Institute	127
Closing date: 17 Feb 22	127
Ethical, legal and social implications research (R01 clinical trial optional)	127
NIH: National Human Genome Research Institute	127
Closing date: 17 Feb 22	128
Ethical, legal and social implications of genomics research – exploratory/developmental research programme (R21 clinical trial optio	nal) 128
NIH: National Human Genome Research Institute	128
Closing date: 17 Feb 22	128
Enabling discovery through GEnomics (EDGE)	128
National Science Foundation	128
Closing date: 17 Feb 22	128
Exploratory data science methods and algorithm development in infection immune-mediated diseases (R21 clinical trial not allowed)	
NIH: National Institute of Allergy and Infectious Diseases	128
Closing date: 17 Feb 22	128
Enhancement or sustainment of data science tools for infectious and imm mediated diseases (U24 clinical trial not allowed)	
NIH: National Institute of Allergy and Infectious Diseases	129
Closing date: 17 Feb 22	129
Early-stage development of data science technologies for infectious and in mediated diseases (U01 clinical trial not allowed)	
NIH: National Institute of Allergy and Infectious Diseases	129
Closing date: 17 Feb 22	129
Age-related macular degeneration (AMD) integrative biology initiative – discovery of AMD pathobiology using patient-derived induced pluripoten cell-derived retinal pigment epithelium (U01 clinical trial not allowed)	129
NIH: National Eye Institute	129
Closing date: 17 Feb 22	129



Translational neural devices programme (UG3/UH3 clinical trial required)1	30
NIH: National Institute of Neurological Disorders and Stroke1	30
Closing date: 18 Feb 221	30
Comparative effectiveness research in clinical neurosciences (UG3/UH3 clinica trial not allowed)1	
NIH: National Institute of Neurological Disorders and Stroke1	30
Closing date: 18 Feb 221	30
Blueprint MedTech translator (UG3/UH3 clinical trial optional)1	30
NIH: National Institute of Neurological Disorders and Stroke1	30
Closing date: 18 Feb 221	30
Advancing Group A Streptococcus vaccine discovery (R01 clinical trial not allowed)1	.30
NIH: National Institute of Allergy and Infectious Diseases1	30
Closing date: 18 Feb 221	31
Fertility status as a marker for overall health (R01 clinical trial optional) $\dots 1$	31
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development1	.31
Closing date: 19 Feb 221	31
Fertility status as a marker for overall health (R21 clinical trial not allowed) $\dots 1$	31
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development1	.31
Closing date: 19 Feb 221	31
Novel assays to address translational gaps in treatment development (UG3/UH clinical trial optional)1	
NIH: National Institute of Neurological Disorders and Stroke1	31
Closing date: 21 Feb 221	31
Innovation grants to nurture initial translational efforts – neurotherapeutic agent characterisation and in vivo efficacy studies (R61/R33 clinical trial not allowed)	32
NIH: National Institute of Neurological Disorders and Stroke1	
Closing date: 22 Feb 221	
Innovation grants to nurture initial translational efforts – assay development a neurotherapeutic agent identification (R61/R33 clinical trial not allowed)1	nd
NIH: National Institute of Neurological Disorders and Stroke1	
Closing date: 22 Feb 221	
Innovation grants to nurture initial translational efforts – development and validation of model systems to facilitate neurotherapeutic discovery (R61/R33 clinical trials not allowed)	}
NIH: National Institute of Neurological Disorders and Stroke1	



Closing date: 22 Feb 22	132
NCI clinical and translational exploratory or developmental studies (R21 ctrial optional)	
NIH: National Cancer Institute	133
Closing date: 22 Feb 22	133
Discovery of biomarkers and biomarker signatures for neurological and neuromuscular disorders (R61/R33 clinical trial optional)	133
NIH: National Institute of Neurological Disorders and Stroke	133
Closing date: 22 Feb 22	133
Innovative biospecimen science technologies for basic and clinical cancer research (R61 clinical trial not allowed)	133
NIH: National Cancer Institute	133
Closing date: 22 Feb 22	133
Secondary analysis of existing datasets in heart, lung and blood diseases a sleep disorders (R21 clinical trial not allowed)	
NIH: National Heart, Lung and Blood Institute	133
Closing date: 26 Feb 22	134
Laboratories to optimise digital health (R01 clinical trial required)	134
NIH: National Institute of Neurological Disorders and Stroke	134
Closing date: 01 Mar 22	134
Transformative nucleic acid sequencing technology innovation and early development (R21 clinical trial not allowed)	134
NIH: National Human Genome Research Institute	
Closing date: 01 Mar 22	
Transformative nucleic acid sequencing technology innovation and early development (R01 clinical trial not allowed)	
NIH: National Human Genome Research Institute	
Closing date: 01 Mar 22	
Transformative nucleic acid sequencing technology innovation and early development (R21 clinical trial not allowed)	
NIH: National Human Genome Research Institute	
Closing date: 01 Mar 22	
Pilot effectiveness trials of interventions for preschoolers with ADHD (R34 clinical trial required)	4
NIH: National Institute of Neurological Disorders and Stroke	
Closing date: 01 Mar 22	
Method to extend research in time award extension request (type 4 clinical	al trial
optional)	135



NIH: National Cancer Institute	135
Closing date: 01 Mar 22	135
Animal genomics programme (U01 clinical trial not allowed)	135
NIH: National Institute on Drug Abuse	135
Closing date: 02 Mar 22	136
Understanding the role of bilingualism in cognitive reserve/resilience in a and AD/ADRD (R01 clinical trial optional)	
NIH: National Institute on Aging	136
Closing date: 03 Mar 22	
Dyadic interpersonal processes and biopsychosocial outcomes (R01 basic experimental studies with humans)	
NIH: National Institutes of Health	136
Closing date: 05 Mar 22	136
Modular R01s in cancer control and population sciences (R01 clinical trial optional)	
NIH: National Cancer Institute	136
Closing date: 07 Mar 22	136
Cutting-edge basic research awards (R21 clinical trial optional)	137
NIH: National Institute on Drug Abuse	137
Closing date: 08 Mar 22	137
Integrated preclinical and clinical AIDS vaccine development programme clinical trial not allowed)	
NIH: National Institute of Allergy and Infectious Diseases	137
Closing date: 09 Mar 22	
Autoantigens and neoantigens function in the aetiology and pathophysiolotype 1 diabetes (R01 clinical trial optional)	
NIH: National Institute of Diabetes and Digestive and Kidney Diseases	137
Closing date: 09 Mar 22	137
Explainable artificial intelligence for decoding and modulating neural circuactivity linked to behaviour (R01 clinical trial optional)	
NIH: National Institute of Neurological Disorders and Stroke	137
Closing date: 10 Mar 22	
Small-cell lung cancer consortium – biology, therapy and resistance (U01 of trial not allowed)	clinical
NIH: National Cancer Institute	
Closing date: 11 Mar 22	138
Clinical relevance of the linkage between environmental toxicant exposure Alzheimer's disease and related dementias (R01 clinical trial not allowed)	es and



NIH: National Institute of Neurological Disorders and Stroke	138
Closing date: 11 Mar 22	138
Extracellular RNA carrier subclasses in processes relevant to substance use disorders or HIV infection (R21 clinical trial not allowed)	
NIH: National Institute on Drug Abuse	138
Closing date: 15 Mar 22	138
HIV vaccine research and design programme (P01 clinical trial not allowed	1)138
NIH: National Institute of Allergy and Infectious Diseases	138
Closing date: 15 Mar 22	139
Research on bat immunology (R21 clinical trial not allowed)	139
NIH: National Institute of Allergy and Infectious Diseases	139
Closing date: 15 Mar 22	139
RePORT international coordinating centre (RICC) (U01 clinical trial not allo	_
NIH: National Institute of Allergy and Infectious Diseases	139
Closing date: 17 Mar 22	139
Early-career grants	139
Human Frontier Science Program	139
Closing date: 18 Mar 22 (Forecast)	139
Behavioural and integrative treatment development programme (R01 clini trial optional)	
NIH: National Institute on Drug Abuse	140
Closing date: 23 Mar 22	140
Behavioural and integrative treatment development programme (R34 clini trial optional)	
NIH: National Institute on Drug Abuse	
Closing date: 23 Mar 22	140
National Center for Medical Rehabilitation Research early-career research (R03 clinical trial optional)	
NIH: Eunice Kennedy Shriver National Institute of Child Health and Hum Development	
Closing date: 30 Mar 22	140
Elucidating the role of nutrition in care and development of preterm infant clinical trial optional)	
NIH: Eunice Kennedy Shriver National Institute of Child Health and Hum Development	
Closing date: 30 Mar 22	140



Promoting reproductive health for adolescents and adults with disabilities (clinical trial optional)	
NIH: Eunice Kennedy Shriver National Institute of Child Health and Huma Development	
Closing date: 30 Mar 22	141
Promoting reproductive health for adolescents and adults with disabilities (clinical trial optional)	
NIH: Eunice Kennedy Shriver National Institute of Child Health and Huma Development	
Closing date: 30 Mar 22	141
Home and community-based physical activity interventions to improve the health of wheelchair users (R01 clinical trial required)	141
NIH: Eunice Kennedy Shriver National Institute of Child Health and Huma Development	
Closing date: 30 Mar 22	141
Notice of special interest – administrative supplements and urgent competit revisions for research on the 2019 novel coronavirus	
NIH: National Institute on Drug Abuse	142
Closing date: 31 Mar 22	142



# Notice of special interest – T32 complementary and integrative health practitioner supplement programme for pre- and postdoctoral candidates

#### **NIH: National Center for Complementary and Integrative Health**

This supports training for predoctoral and postdoctoral candidates with professional clinical complementary and integrative health degrees through

administrative supplements. Grants are for a period of one to three years.

Closing date: 03 Jan 22

**Link to \*Research Professional** 

# Notice of special interest – small business initiatives for innovative diagnostic technology for improving outcomes for maternal health

#### NIH: National Institute of Biomedical Imaging and Bioengineering

This aims to encourage interest in the small business community to develop various approaches, technologies and tools to address the health issues of maternal morbidity.

Closing date: 05 Jan 22

**Link to \*Research Professional** 

### <u>Limited competition – modular budget research project grant</u> <u>for NIH nurse scientist scholars (R01 clinical trial optional):</u> AIDS-related

#### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity supports research projects conducted by NIH-supported nurse scientists in order to help accelerate their transition to independent investigator status.

Application budgets are worth up to USD 250,000 in direct costs per year for up to five years.

Closing date: 06 Jan 22

**Link to \*Research Professional** 

## HIV infection of the central nervous system (R01 clinical trial not allowed)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports research projects that focus on delineating the pathophysiology of HIV-1 associated

central nervous system disease in the setting of chronic viral suppression and antiretroviral



therapy. The maximum project period is five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### <u>Dissemination and implementation research in health (R21 clinical trial optional)</u>: AIDS-related

#### **NIH: National Cancer Institute**

This supports AIDS-related innovative approaches to identifying and developing strategies to disseminate and implement evidence-based practices into public public health, clinical practice and

community settings. Grants are worth up to USD 275,000 each for two years.

Closing date: 07 Jan 22

Link to \*Research Professional

## <u>Imaging – science track award for research transition (R03 clinical trial optional): AIDS-related</u>

#### **NIH: National Institute on Drug Abuse**

This AIDS-related announcement facilitates the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programmes, to enable them to

conduct small proof of concept studies. Awards are worth up to USD 150,000 for a maximum period of one year.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### Small research grant programme (parent R03 clinical trial not allowed): AIDS-related

#### NIH: National Human Genome Research Institute

This supports small AIDS-related research projects that can be carried out in a short period of time with limited resources. Awards are worth

up to USD 50,000 in direct costs per year for up to two years.

Closing date: 07 Jan 22



### Exploratory or developmental research grant programme (parent R21 clinical trial not allowed): AIDS-related

#### **NIH: National Eye Institute**

This AIDS-related funding opportunity supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Application budgets are

limited to USD 275,000 for a twoyear period, with no more than USD 200,000 in any year.

Closing date: 07 Jan 22

Link to \*Research Professional

## NEI research grant for vision related secondary data analysis (R21 clinical trial not allowed): AIDS-related

#### **NIH: National Eye Institute**

This AIDS-related opportunity supports vision-related secondary data analyses utilising existing database resources. Grants are worth up to to USD 275,000 for a maximum period of two years.

Closing date: 07 Jan 22

Link to \*Research Professional

### **Exploratory/developmental bioengineering research grants** (R21 clinical trial optional): AIDS-related

#### **NIH: National Cancer Institute**

This AIDS-related call supports the demonstration of feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, preclinical or clinical research, clinical care delivery or accessibility. Direct costs are limited to USD 275,000 over a two-year period.

Closing date: 07 Jan 22

Link to \*Research Professional

### Bioengineering research grants (R01 clinical trial required): AIDS-related

#### NIH: National Institute of Biomedical Imaging and Bioengineering

These AIDS-related grants support collaborations between the life and physical sciences that apply a multidisciplinary bioengineering approach to the solution of a biomedical problem. Grants are for up to five years.



Closing date: 07 Jan 22 <u>Link to \*Research Professional</u>

### Research project grant (parent R01 basic experimental studies with humans required): AIDS-related

#### **NIH: National Eye Institute**

This supports a discrete, specified, circumscribed AIDS-related project in areas representing the specific interests and competencies of the

investigators. The maximum project period is five years.

Closing date: 07 Jan 22

Link to \*Research Professional

### AIDS-science track award for research transition (R03 clinical trial optional)

#### **NIH: National Institute on Drug Abuse**

This seeks to facilitate the entry of both newly independent and earlycareer investigators to the area of drug abuse research on HIV/AIDS. Awards are each worth up to USD 100,000 per year for a maximum period of two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

## Bioengineering research partnerships (U01 clinical trial required): AIDS-related

#### NIH: National Institute of Biomedical Imaging and Bioengineering

This AIDS-related funding opportunity encourages bioengineering applications that will accelerate the development and adoption of tools and technologies that can address important

biomedical problems. The maximum project period is five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

National Institute of Dental and Craniofacial Research small grant programme for new investigators (R03 clinical trial not allowed): AIDS-related

NIH: National Institute of Dental and Craniofacial Research



This AIDS-related opportunity supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research.

Grants are worth up to USD 200,000 over a maximum period of two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### NLM research grants in biomedical informatics and data science (R01 clinical trial optional): AIDS-related

#### **NIH: National Library of Medicine**

This AIDS-related opportunity supports innovative research and development in biomedical informatics and data science. Grants are worth up to USD 250,000 each

per year over a maximum period of four years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### <u>Pilot and feasibility studies in preparation for drug and alcohol</u> <u>abuse prevention trials (R34 clinical trial optional): AIDS-</u> <u>related</u>

#### **NIH: National Institute on Drug Abuse**

This AIDS-related opportunity supports research that provides intervention pilot or feasibility data serving as a prerequisite for subsequent applications for larger scale drug or alcohol abuse prevention or drug- or alcohol-

related HIV prevention intervention studies. Grants are worth up to USD 450,000 each over three years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

## <u>Drug discovery for nervous system disorders (R21 clinical trial not allowed): AIDS-related</u>

#### NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related call supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Grants

are worth up to USD 275,000 each over two years.

Closing date: 07 Jan 22



### <u>Drug discovery for nervous system disorders (R01 clinical trials</u> not allowed): AIDS-related

#### NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related funding opportunity supports the discovery of novel compounds for the prevention and treatment of nervous

system disorders. Funding is for up to five years.

Closing date: 07 Jan 22

Link to \*Research Professional

### <u>EXTENDED DEADLINE: Accelerating the pace of drug abuse</u> <u>research using existing data (R01 clinical trial optional): AIDS-</u> related

#### **NIH: National Institute on Drug Abuse**

This AIDS-related opportunity supports the innovative analysis of existing social science, behavioural, administrative and neuroimaging data to study the aetiology and epidemiology of drug-using behaviours and related disorders,

prevention of drug use and HIV and health service use. Grants are worth up to USD 499,999 per year over a maximum period of five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### NINDS efficacy clinical trials (UG3/UH3 clinical trial required): AIDS-related

#### NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related funding opportunity supports investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke. Application budgets are not limited, but need to

reflect the actual needs of the project. The maximum project period is five years.

Closing date: 07 Jan 22

Link to \*Research Professional

## <u>Discovery of in vivo chemical probes for the nervous system</u> (R01 clinical trial not allowed): AIDS-related

#### NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related opportunity supports research on in vivo chemical probes for novel brain

targets. Projects may last up to four years.



Closing date: 07 Jan 22 <u>Link to \*Research Professional</u>

## Development and testing of novel interventions to improve HIV prevention, care and programme implementation (R34 clinical trial optional)

#### **NIH: National Institute on Drug Abuse**

This supports formative research, intervention development and pilottesting of HIV interventions among populations where substance use may be a contributing factor. Grants

are worth up to USD 450,000 each over three years.

Closing date: 07 Jan 22

Link to \*Research Professional

## <u>Dissemination and implementation research in health (R01 clinical trial optional): AIDS-related</u>

#### **NIH: National Cancer Institute**

This supports innovative AIDS-related approaches that aim to identify and develop strategies to disseminate and implement evidence-based practices into public health, clinical practice, and community settings. Application

budgets are not limited. The maximum project period is five years.

Closing date: 07 Jan 22

Link to \*Research Professional

### <u>Dissemination and implementation research in health (R03</u> clinical trial not allowed): AIDS-related

#### **NIH: National Cancer Institute**

This AIDS-related announcement supports innovative approaches to identifying, understanding and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based

interventions, tools, policies and guidelines. Grants are worth up to USD 50,000 per year for a maximum period of two years.

Closing date: 07 Jan 22



### Sustained release of antivirals for treatment or prevention of HIV (R01 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports research that addresses the long term goal and objective of developing sustained release strategies for HIV treatment or prevention. The maximum project period is five years.

Closing date: 07 Jan 22

Link to \*Research Professional

## New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 clinical trial not allowed): AIDS-related

#### NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related opportunity supports the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with

mental disorders. The maximum project period is five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### <u>Eradication of HIV-1 from central nervous system reservoirs</u> (R01 clinical trial not allowed)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system in the context of viral suppression. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 07 Jan 22

Link to \*Research Professional

## <u>Collaborative clinical vision project – resource centre grant</u> (UG1 clinical trial required): AIDS-related

#### **NIH: National Eye Institute**

This AIDS-related call supports investigator-initiated large-scale clinical trials, human gene-transfer

and stem cell therapy trials, and other complex or high resource or safety-risk clinical trials. Application



budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period is five years. Closing date: 07 Jan 22

Link to \*Research Professional

### <u>Collaborative clinical vision research – chair's grant (UG1</u> clinical trial required): AIDS-related

#### **NIH: National Eye Institute**

This AIDS-related call supports investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. Application

budgets are not limited, but must reflect the actual needs of the project.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### <u>Collaborative clinical vision research project – coordinating</u> centre grant (UG1 clinical trial required): AIDS-related

#### **NIH: National Eye Institute**

This AIDS-related funding opportunity supports investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other demanding

clinical trials. Funding is for up to five years.

Closing date: 07 Jan 22

Link to \*Research Professional

# Innovations in HIV testing, adherence and retention to optimise HIV care continuum outcomes (R01 clinical trial optional)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports innovative research to optimise HIV prevention and care. The maximum project period is five years.

Closing date: 07 Jan 22



## End-of-life and palliative needs of adolescents and young adults with serious illnesses (R21 clinical trial optional): AIDS-related

#### **NIH: National Institute of Nursing Research**

This AIDS-related announcement aims to foster research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses. Direct costs are limited to USD 275,000 over a two-year period.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

# End-of-life and palliative needs of adolescents and young adults with serious illnesses (R01 clinical trial optional): AIDS-related

#### **NIH: National Institute of Nursing Research**

This AIDS-related opportunity supports research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses.

Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

## Small research grants for oral health data analysis and statistical methodology development (R03 clinical trial not allowed): AIDS-related

#### NIH: National Institute of Dental and Craniofacial Research

This AIDS-related opportunity supports research projects that involve secondary data analyses of existing oral or craniofacial database resources, or the development of needed statistical methodology for analysing oral and craniofacial data using existing oral or craniofacial databases. Funding is worth up to USD 200,000 per project over two years.

Closing date: 07 Jan 22



# Innovations in HIV prevention, testing, adherence and retention to optimise HIV prevention and care continuum outcomes (R21 clinical trial optional)

#### NIH: National Institute of Neurological Disorders and Stroke

This encourages research in formative basic behavioural and social science to better understand a single step or steps in the HIV prevention or care continuum, or the initial development and pilot testing of innovative intervention

approaches. Application budgets are limited to USD 275,000 for up to two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

## Extracellular RNA carrier subclasses in processes relevant to substance use disorders or HIV infection (R01 clinical trial not allowed): AIDS-related

#### **NIH: National Institute on Drug Abuse**

This supports AIDS-related research investigating the roles of extracellular RNA carrier subclasses in biological processes relevant to substance use disorders or HIV infection, latency or pathogenesis in

the central nervous system. The maximum project period is five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

## <u>Clinical studies of mental illness (collaborative R01 clinical trial optional): AIDS-related</u>

#### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related funding opportunity supports collaborative clinical studies that do not involve treatment development, efficacy or

effectiveness trials. The maximum project period is five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### Multidisciplinary studies of HIV/AIDS and ageing (R21 clinical trial optional)

#### **NIH: National Institute on Aging**

This supports studies that aim to improve understanding of aspects of

ageing through the lens of HIV infection and its treatment, as well



as improve approaches for testing of HIV infection and management of HIV-related complications in different populations and cultural settings. Awards are worth up to USD 275,000 each for two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### Multidisciplinary studies of HIV/AIDS and ageing (R01 clinical trial optional)

#### **NIH: National Institute on Aging**

This supports studies addressing HIV and ageing that aim to improve understanding of biological, clinical and socio-behavioural aspects of ageing through the lens of HIV infection. Application budgets are not limited but need to reflect the

actual needs of the proposed project. The maximum project period is five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

## <u>Discovery of cell-based chemical probes for novel brain</u> targets (R21 clinical trial not allowed): AIDS-related

#### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related opportunity supports investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. Grants are worth up to USD 275,000 over a two-year period.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

## Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 clinical trial not allowed): AIDS-related

#### **NIH: National Cancer Institute**

This supports AIDS-related research in discovery and development of novel, small molecules for their potential use in studying disease treatment, and to generate new insight into the biology of relevant diseases and processes that are not yet drug targets. The maximum project perios is four years.

Closing date: 07 Jan 22



### <u>Understanding and modifying temporal dynamics of</u> <u>coordinated neural activity (R21 clinical trial optional): AIDS-</u> related

#### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related call supports projects that test whether modifying electrophysiological patterns during behaviour can improve cognitive, affective, or social processing. The combined budget for direct costs for

the two-year project period may not exceed USD 275,000.

Closing date: 07 Jan 22

Link to \*Research Professional

## <u>Understanding and modifying temporal dynamics of</u> <u>coordinated neural activity (R01 clinical trial optional): AIDS-</u> related

#### NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related call supports research to lay the groundwork for developing systems-level neuroscience interventions into treatments for cognitive, affective or social deficits in psychiatric disorders. Application budgets are

not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### <u>Exploratory or developmental research grant programme</u> (parent R21 clinical trial required): AIDS-related

#### **NIH: National Eye Institute**

This supports AIDS-related exploratory and developmental research projects in their early and conceptual stages. Awards are worth

up to USD 275,000 in direct costs for up to two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### Joint NINDS/NIMH exploratory neuroscience research grant (R21 clinical trial optional): AIDS-related

#### NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related announcement supports exploratory and innovative

research projects, which fall within the mission of the National Institute



of Neurological Disorders and Stroke and the National Institute of Mental Health. Grants are worth up to USD 275,000 for two years. Closing date: 07 Jan 22

Link to \*Research Professional

### Research project grant (parent R01 clinical trial not allowed): AIDS-related

#### **NIH: National Eye Institute**

This supports a discrete, specified and circumscribed AIDS-related project in areas representing the specific interests and competencies of the investigators. The maximum project period is five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### <u>Cancer prevention and control clinical trials grant programme</u> (R01 clinical trial required): AIDS-related

#### **NIH: National Cancer Institute**

This AIDS-related announcement supports investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, prevention, healthcare delivery, quality of life or

survivorship related to cancer. The maximum project period is five years.

Closing date: 07 Jan 22

Link to \*Research Professional

# <u>Pilot and feasibility studies of HIV and animal models for HIV infection within the mission of the NIDDK (R21 clinical trial not allowed): AIDS-related</u>

#### NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This AIDS-related opportunity supports basic and translational research projects examining HIV infection, persistence, and comorbidities relevant to the the institute's study of diabetes and

other endocrine and metabolic diseases. Grants are worth up to USD 275,000 each for up to two years.

Closing date: 07 Jan 22



## NIDA small research grant programme (R03 clinical trial required): AIDS-related

#### **NIH: National Institute on Drug Abuse**

This supports small clinical trials that can be carried out in a short period of time with limited resources. Grants are worth up to

USD 50,000 each per year for up to two years.

Closing date: 07 Jan 22

Link to \*Research Professional

## Small research grants for analyses of Gabriella Miller Kids First paediatric research data (R03 clinical trial not allowed): AIDS-related

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports meritorious small AIDS-related research projects that involve analyses of genomic, phenotypic or clinical datasets that are part of the Kids First programme, and projects that develop approaches, tools or

algorithms to support or enhance analyses of these data. Grants are worth up to USD 200,000 each over two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### Vision research epidemiology grant (UG1 clinical trial not allowed): AIDS-related

#### **NIH: National Eye Institute**

This supports AIDS-related epidemiologic studies that use creative and innovative approaches to studying vision diseases and disorders with high public impact, to inform prevention and treatment

strategies as well as basic sciences research. Funding is for up to five years.

Closing date: 07 Jan 22

Link to \*Research Professional

Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R03 clinical trial optional): AIDS-related

National Institute on Alcohol Abuse and Alcoholism



This AIDS-related opportunity supports research on how alcohol and other illicit drugs or illicitly-used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent or reduce simultaneous use of

alcohol or drugs singly or in combination. Grants are each worth up to USD 50,000 per year for a maximum period of two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

# New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 (collab) clinical trial not allowed): AIDS-related

#### NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related opportunity supports the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex

aetiologies identified through genome-wide association or sequencing studies. Funding is for up to five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### Applying a biopsychosocial perspective to self-management of chronic pain (R01 clinical trial optional): AIDS-related

#### **NIH: National Institute of Nursing Research**

This supports the applications of a biopsychosocial perspective to selfmanagement of chronic pain with a focus on AIDS. The maximum project period is five years.

Closing date: 07 Jan 22

Link to \*Research Professional

## Biobehavioural basis of chronic pain (R01 clinical trial optional): AIDS-related

#### **NIH: National Institute of Nursing Research**

This AIDS-related opportunity supports studies on the biobehavioural basis of chronic pain with a focus on the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional

components that underpin the individual's chronic pain experience. The maximum project period is five years.

Closing date: 07 Jan 22



### Applying a biopsychosocial perspective to self-management of chronic pain (R21 clinical trial optional): AIDS-related

#### **NIH: National Institute of Nursing Research**

This supports the applications of a biopsychosocial perspective to selfmanagement of chronic pain with a focus on AIDS. Grants are worth up to USD 275,000 for two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### Biobehavioural basis of chronic pain (R21 clinical trial optional): AIDS-related

#### **NIH: National Institute of Nursing Research**

This supports AIDS-related research that focuses on the individual phenotype, genotype and other omic-type assessments and the associated sensory and emotional components that underpin the individual's chronic pain experience.

Grants are worth up to USD 275,000 each over a maximum period of two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

## Fc-dependent mechanisms of antibody-mediated killing (R21 clinical trial not allowed): AIDS-related

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports AIDS-related research that aims to improve the understanding of Fc-dependent, antibody-mediated killing of pathogen-infected or otherwise dysregulated host cells. Grants are each worth up to USD 275,000 over a maximum of two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### Addressing caregiver symptoms through technological tools (R01 clinical trial optional): AIDS-related

#### **NIH: National Institute of Nursing Research**

This supports the development and testing of tools to address symptoms

in caregivers, regardless of patient symptoms or conditions, with a



focus on AIDS. The project may last up to five years.

Closing date: 07 Jan 22

Link to \*Research Professional

### Addressing caregiver symptoms through technological tools (R21 clinical trial optional): AIDS-related

#### **NIH: National Institute of Nursing Research**

This supports AIDS-related research focused on the development and testing of tools to address symptoms in caregivers, regardless of patient symptoms or conditions. Grants are

worth up to USD 275,000 each over a maximum period of two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

## Advancing research in augmentative and alternative communication (R01 clinical trial optional): AIDS-related

#### NIH: National Institute on Deafness and other Communication Disorders

This AIDS-related funding opportunity supports research on augmentative and alternative communication to advance scientific knowledge in the evaluation and treatment of individuals with complex communication needs or

with severe speech and physical impairments. The maximum project period is five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

## End-of-life and palliative care approaches to advanced signs and symptoms (R01 clinical trial optional): AIDS-related

#### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity supports the examination of the multi-dimentional foundation, experiences and management of complex, advanced signs and symptoms at the

end of life. The project may last up to five years.

Closing date: 07 Jan 22



### Advancing research in augmentative and alternative communication (R21 clinical trial optional): AIDS-related

#### NIH: National Institute on Deafness and other Communication Disorders

This AIDS-related funding opportunity supports research on augmentative and alternative communication to advance scientific knowledge in the evaluation and treatment of individuals with complex communication needs or

with severe speech and physical impairments. Grants are worth up to USD 275,000 for a maximum period of two years.

Closing date: 07 Jan 22

Link to \*Research Professional

### End-of-life and palliative care approaches to advanced signs and symptoms (R21 clinical trial optional): AIDS-related

#### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity supports the examination of the multi-dimentional foundation, experiences and management of complex, advanced signs and symptoms at the

end of life. Grants are worth up to USD 275,000 each over a maximum period of two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### Strategies to provide culturally tailored palliative and end-oflife care for seriously ill American Indian and Alaska Native individuals (R01 clinical trial optional): AIDS-related

#### **NIH: National Institute of Nursing Research**

This supports AIDS-related research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care for American Indian or Alaska Native individuals with advanced illness and their families and communities. Funding is for five years.

Closing date: 07 Jan 22

Link to \*Research Professional

Strategies to provide culturally tailored palliative and end-oflife care for seriously ill American Indian and Alaska Native individuals (R21 clinical trial optional): AIDS-related

**NIH: National Institute of Nursing Research** 



This supports AIDS-related research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care for American Indian and Alaska Native individuals with advanced illness and their families and communities.

Grants are worth up to USD 275,000 each over a maximum period of two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### <u>Processing and presentation of non-conventional MHC ligands</u> (R01 clinical trial not allowed): AIDS-related

#### **NIH: National Institute of Allergy and Infectious Diseases**

This AIDS-related funding opportunity supports the determination of antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptiic ligands and of the contribution of these unique

antigenic ligands to protective immune responses. The maximum project period is five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### <u>Processing and presentation of non-conventional MHC ligands</u> (R21 clinical trial not allowed): AIDS-related

#### **NIH: National Institute of Allergy and Infectious Diseases**

This AIDS-related funding opportunity supports the determination of antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptiic ligands and of the contribution of these unique

antigenic ligands to protective immune responses. Grants are worth up to USD 275,000 each for a maximum period of two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

## <u>Telomeres in wellness and disease – a biobehavioural approach (R01 clinical trial optional): AIDS-related</u>

#### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity aims to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies

into biobehavioural programmes of research. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.



Closing date: 07 Jan 22 <u>Link to \*Research Professional</u>

### <u>Telomeres in wellness and disease – a biobehavioural</u> approach (R21 clinical trial optional): AIDS-related

#### **NIH: National Institute of Nursing Research**

This AIDS-related funding opportunity aims to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioural programmes of

research. Grants are worth up to USD 275,000 each for a maximum period of two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

# Exploratory or developmental research grant programme (parent R21 basic experimental studies with humans required): AIDS-related

#### **NIH: National Eye Institute**

This supports AIDS-related exploratory and developmental research projects in the early and conceptual stages. Awards are worth

up to USD 275,000 in direct costs for up to two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

# Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis and other select endemic fungal infections (R01 clinical trial not allowed): AIDS-related

#### **NIH: National Institute of Allergy and Infectious Diseases**

This AIDS-related opportunity supports research that contributes to the overall understanding of coccidioidomycosis and other select endemic fungal diseases including histoplasmosis and blastomycosis.

The maximum project period is five years.

Closing date: 07 Jan 22



# Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis and other select endemic fungal infections (R21 clinical trial not allowed): AIDS-related

#### **NIH: National Institute of Allergy and Infectious Diseases**

This AIDS-related funding opportunity supports research that contributes to the overall understanding of coccidioidomycosis and other select endemic fungal diseases, including histoplasmosis and blastomycosis.

Grants are worth up to USD 275,000 each for a maximum period of two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### Bioengineering research grants (R01 clinical trial not allowed): AIDS-related

#### NIH: National Institute of Biomedical Imaging and Bioengineering

This AIDS-related call supports collaborations between the life and physical sciences that apply a multidisciplinary bioengineering approach to the solution of a

biomedical problem. Grants are for up to five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

## Bioengineering research partnerships (U01 clinical trial not allowed): AIDS-related

#### NIH: National Institute of Biomedical Imaging and Bioengineering

This AIDS-related call encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The

maximum project period is five years.

Closing date: 07 Jan 22

Link to \*Research Professional

### **Exploratory/developmental bioengineering research grants** (R21 clinical trial not allowed): AIDS-related

#### **NIH: National Cancer Institute**

This AIDS-related call supports the demonstration of feasibility and potential utility of new capabilities

or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems



in basic biomedical, pre-clinical or clinical research, clinical care delivery or accessibility. Direct costs are limited to USD 275,000 over a two-year period.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

# EXTENDED DEADLINE: Accelerating the pace of child health research using existing data from the adolescent brain cognitive development study (R21 clinical trial not allowed): AIDS-related

#### **NIH: National Institute on Drug Abuse**

This AIDS-related call supports the analysis of public data to increase knowledge of adolescent health and

development. Grants are worth up to USD 275,000 each for two years.

Closing date: 07 Jan 22

Link to \*Research Professional

### <u>Comparative effectiveness research in clinical neurosciences</u> (UG3/UH3 clinical trial not allowed): AIDS-related

#### NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related call supports prospective observational comparative effectiveness research evaluating preventive strategies, diagnostic approaches or interventions including drugs, biologics and devices or surgical,

behavioural and rehabilitation therapies. The maximum project period is seven years.

Closing date: 07 Jan 22

Link to \*Research Professional

## Clinical research study planning grant programme (R34 clinical trial not allowed): AIDS-related

#### **NIH: National Eye Institute**

This AIDS-related funding opportunity supports the refinement of a study protocol and procedures and the development of a detailed manual of procedures, as well as preliminary studies to refine study procedures or document

recruitment potential. Grants are worth up to USD 150,000 each per year for up to two years.

Closing date: 07 Jan 22



## Novel RNAs in virology and immune regulation – basic science and therapeutic discovery (R21 clinical trial not allowed): AIDS-related

#### **NIH: National Institute of Allergy and Infectious Diseases**

This AIDS-related opportunity supports basic science research in novel biologically active viral or host RNAs involved in virology, including HIV biology, and immune regulation.

Grants are worth up to USD 275,000 for two years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### Exploratory clinical neuroscience research on substance use disorders (R61/R33 clinical trial optional): AIDS-related

#### **NIH: National Institute on Drug Abuse**

This supports exploratory and developmental AIDS-related clinical research that focuses on understanding the neurobiological mechanisms underlying substance use disorders, including

fundamental brain function relevant to substance use. The maximum funding period is five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### Mechanisms of tolerance (R21/R33 clinical trial required): AIDS-related

#### **National Institute on Alcohol Abuse and Alcoholism**

This AIDS-related funding opportunity supports research on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder.

Grants are worth up to USD 1.77 million each for up to five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

Development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and for pathophysiological studies of CNS disorders (R01 clinical trial optional): AIDS-related

#### **NIH: National Institute of Neurological Disorders and Stroke**

This AIDS-related opportunity supports research on the

development of novel radioligands for positron emission tomography or



single photon emission computed tomography imaging in human brain, and that incorporate pilot or clinical feasibility evaluation in preclinical studies. The maximum project period is four years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

Development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and for pathophysiological studies of central nervous system disorders (R01 clinical trial not allowed): AIDS-related

#### NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related call supports the preclinical development of novel radioligands for positron emission tomography or single photon emission computed tomography imaging in rodent and nonhuman primate brain and incorporation of

pilot or clinical feasibility evaluation in preclinical studies. Grants are worth up to USD 275,000 each for up to three years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

## Catalytic tool and technology development in kidney, urological and haematological diseases (R21 clinical trial not allowed): AIDS-related

#### NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This AIDS-focused opportunity supports the development of innovative, enabling tools and technologies in the areas of kidney, urological and haematological diseases. Grants are worth up to USD 275,000 each for up to two years.

Closing date: 07 Jan 22

Link to \*Research Professional

### Biomedical data repository (U24 clinical trials not allowed): AIDS-related

#### **NIH: National Institute of General Medical Sciences**

This supports AIDS-related biomedical data repositories whose primary function is to ingest, archive, preserve, manage, distribute, and make accessible the data related to a particular system or systems. The maximum project period is five years.

Closing date: 07 Jan 22



### <u>Biomedical knowledgebase (U24 clinical trials not allowed):</u> AIDS-related

#### NIH: National Institute of General Medical Sciences

This AIDS-related call supports the extraction, accumulation, organisation, annotation and linking of growing bodies of information related to core datasets. The

maximum project period is five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### Research project grant (parent R01 clinical trial required): AIDS-related

#### **NIH: National Eye Institute**

This supports a discrete, specified, circumscribed AIDS-related project in areas representing the specific interests and competencies of the

investigators. The maximum project period is five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

# HEAL initiative – non-addictive analgesic therapeutics development to treat pain (UG3/UH3 clinical trial not allowed): AIDS-related

#### NIH: National Institute of Neurological Disorders and Stroke

This supports AIDS-related research that includes preclinical optimisation and development of safe, effective and non-addictive small molecule and biologic therapeutics to treat pain. The

maximum project period is five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

### Notice of special interest – telehealth strategies for individuals with HIV and substance use disorders

#### **NIH: National Institute on Drug Abuse**

This supports research exploring and developing telehealth methods

and strategies for diagnosis, prevention, treatment, and



population analysis in individuals living with HIV and substance use disorders.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

# Blueprint neurotherapeutics network – biologic-based drug discovery and development for disorders of the nervous system (UG3/UH3 clinical trial optional): AIDS-related

#### NIH: National Institute of Neurological Disorders and Stroke

This AIDS-related opportunity supports preclinical discovery and development of potential therapeutic biotechnology products and biologics, gene-based therapies, cell therapies and novel emerging therapies. The maximum project period is five years.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

#### Notice of special interest – harnessing big data to halt HIV

#### **NIH: National Institute of Allergy and Infectious Diseases**

This aims to promote and support innovative methods in big data science to identify unappreciated biomedical, behavioural, social patterns and other social determinants that shed light on HIV acquisition, transmission, the

development of comorbidities, and long-term viral control as in the HIV treatment continuum.

Closing date: 07 Jan 22

Link to \*Research Professional

### Notice of special interest – HIV/AIDS in the era of COVID-19, when pandemics collide

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports research that can quantify and describe the impact of COVID-19 acute and post-acute

disease on the HIV/AIDS epidemic in the United States and worldwide.

Closing date: 07 Jan 22



### <u>Paediatric immune system – ontogeny and development (R01 clinical trial not allowed): AIDS-related</u>

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This AIDS-related funding opportunity aims to correlate immune system in general and development patterns in particular, between two or more age groups, and further understand the impact of infectious diseases, microbiome and environmental

factors on the ontogeny and development of the pediatric immune system. Grants are worth up to USD 400,000 per year over four years.

Closing date: 07 Jan 22

Link to \*Research Professional

# Imaging - science track award for research transition (R03 basic experimental studies with humans required): AIDS-related

#### **NIH: National Institute on Drug Abuse**

This AIDS-related announcement facilitates the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programmes, to enable them to

conduct small proof of concept studies. Awards are worth up to USD 150,000 for a maximum period of one year.

Closing date: 07 Jan 22

**Link to \*Research Professional** 

# Notice of special interest – fundamental and translational research on decision making in ageing and Alzheimer's disease and Alzheimer's disease related dementias

#### **NIH: National Institute on Aging**

This supports fundamental and translational research on decision making in normal ageing as well as in individuals with mild cognitive impairment, Alzheimer's disease and

Alzheimer's disease-related dementias.

Closing date: 08 Jan 22



### Notice of special interest – bold new engineering research for heart, lung, blood and sleep disorders and diseases

#### NIH: National Heart, Lung and Blood Institute

This supports early phases of innovative bioengineering projects which are expected to transition their research into future follow-on

funding, technologies, or commercial products.

Closing date: 08 Jan 22

Link to \*Research Professional

### Myeloid-derived suppressor cells as potential therapeutic targets in TB/HIV (R01 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports innovative clinical, preclinical and non-clinical research to determine the potential of myeloid-derived suppressor cells as a target for host-directed therapeutics for tuberculosis in the

context of HIV co-infection. The maximum project period is five years.

Closing date: 10 Jan 22

**Link to \*Research Professional** 

### Myeloid-derived suppressor cells as potential therapeutic targets in TB/HIV (R21 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports innovative clinical, preclinical and non-clinical research to determine the potential of myeloid-derived suppressor cells as a target for host-directed therapeutics for tuberculosis in the

context of HIV co-infection. Grants are worth up to USD 275,000 for two years.

Closing date: 10 Jan 22

Link to \*Research Professional

### Integrating biospecimen science approaches into clinical assay development (U01 clinical trial not allowed)

#### **NIH: National Cancer Institute**

This supports the investigation and mitigation of challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumour

tissue biopsies, blood biospecimens used as liquid biopsies or other biospecimens. Grants are worth up to USD 250,000 per year for a maximum period of five years.



Closing date: 11 Jan 22 <u>Link to \*Research Professional</u>

### NIAID clinical trial planning grant (R34 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports the planning, design and preparation of the documentation necessary for implementation of investigatorinitiated clinical trials. Grants are worth up to USD 150,000 each for a maximum period of one year.

Closing date: 12 Jan 22

**Link to \*Research Professional** 

#### **Programme grants**

#### **Human Frontier Science Program**

These support teams of researchers at any career stage working on innovative approaches to understand complex mechanisms of living organisms. Grants are worth up to USD 465,000 per year each

over three years, dependent upon team size.

Closing date: 13 Jan 22 (Forecast)
Link to \*Research Professional

### NIAID clinical trial implementation cooperative agreement (U01 clinical trial required)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Application budgets are not limited but must

reflect the actual needs of the proposed project. The maximum funding period is five years.

Closing date: 14 Jan 22

**Link to \*Research Professional** 

### Single-site investigator-initiated clinical trials (R61/R33 clinical trial required): AIDS-related

#### NIH: National Heart, Lung and Blood Institute

This AIDS-related call supports the development and implementation of

investigator-initiated single-site clinical trials relevant to the



research mission of the National Heart, Lung and Blood Institute. The maximum project period is five years. Closing date: 14 Jan 22

Link to \*Research Professional

### Systems biology for infectious diseases (U19 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports research that employs systems biology approaches to human pathogens, in order to predict disease severity, responses to vaccines and therapeutics, and identifying candidate targets for

interventions. Awards are worth up to USD 1.5 million each per year for up to five years.

Closing date: 14 Jan 22

**Link to \*Research Professional** 

### Clinical coordinating centre for multi-site investigatorinitiated clinical trials (collaborative UG3/UH3 clinical trial required): AIDS-related

#### NIH: National Heart, Lung and Blood Institute

This AIDS-related funding opportunity supports the development and implementation of a clinical coordinating centre for investigator-initiated multi-site clinical trials that are relevant to the research mission of the National

Heart, Lung and Blood Institute. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 14 Jan 22

Link to \*Research Professional

### <u>Data coordinating centre for multi-site investigator-initiated</u> <u>clinical trials (collaborative U24 clinical trial required): AIDS-</u> related

#### **NIH: National Heart, Lung and Blood Institute**

This AIDS-related call supports the implementation of a collaborating data coordinating centre for investigator-initiated multi-site clinical trials that are relevant to the research mission of the National Heart, Lung, and Blood Institute.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 14 Jan 22



### Administrative supplements for research on dietary supplements (admin supp clinical trial not allowed)

#### **NIH: National Institutes of Health**

This supports research in which the supplemental funding investigates the role of dietary supplements or their ingredients in health maintenance and disease prevention. Grants are worth up to

USD 100,000 in direct costs for one year.

Closing date: 15 Jan 22

**Link to \*Research Professional** 

### <u>Developing digital therapeutics for substance use disorders</u> (UG3/UH3 clinical trial optional): Aids-related

#### **NIH: National Institute on Drug Abuse**

This AIDS-related funding opportunity supports research projects to accelerate the development of digital therapeutics (DTx) to treat substance use disorders (SUDs). Awards are worth

USD 500,000 in direct costs per year over three years.

Closing date: 17 Jan 22

**Link to \*Research Professional** 

# <u>Cellular senescence network – technology development and application in murine systems (UG3/UH3 clinical trial not allowed)</u>

#### **NIH: Office of the Director**

This supports research examining novel analytics and technologies to identify and map senescent cells in murine tissues at high resolution. Up to three awards, worth up to USD 350,000 per year for up to two years

and up to USD 500,000 per year for up to three years, are available for a maximum project period of 4 years.

Closing date: 19 Jan 22

**Link to \*Research Professional** 

### <u>Collaborative clinical vision project – resource centre grant</u> (UG1 clinical trial required)

**NIH: National Eye Institute** 



This supports investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex, high-resource or safety-risk clinical trials. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum period is five years.

Closing date: 25 Jan 22

**Link to \*Research Professional** 

### <u>Collaborative clinical vision research – chair's grant (UG1</u> clinical trial required)

#### **NIH: National Eye Institute**

This supports investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex, high resource or safety-risk clinical trials. Application budgets are not limited,

but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 25 Jan 22

**Link to \*Research Professional** 

### <u>Collaborative clinical vision research project – coordinating</u> centre grant (UG1 clinical trial required)

#### **NIH: National Eye Institute**

This supports investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex, high-resource or safety-risk clinical trials. Application budgets are not limited,

but must reflect the actual needs of the project. The maximum project period is five years.

Closing date: 25 Jan 22

**Link to \*Research Professional** 

### **Genomic community resources (U24 clinical trial not allowed)**

#### **NIH: National Human Genome Research Institute**

This supports the development and distribution of genomic resources that will be available to and valuable for the broad research community,

using cost-effective approaches. The maximum period is five years.

Closing date: 25 Jan 22



### <u>Vision research epidemiology grant (UG1 clinical trial not allowed)</u>

### **NIH: National Eye Institute**

This supports epidemiologic studies that use creative and innovative approaches to studying vision diseases and disorders with high public impact, to inform prevention and treatment strategies as well as

basic sciences research. Funding is for up to five years.

Closing date: 25 Jan 22

Link to \*Research Professional

### **Genomic data repositories and knowledgebases**

#### NIH: National Human Genome Research Institute

This supports the establishment of new, or continued development of established genomic data resources that use state-of-the-art and costeffective technologies and approaches, and that are of high value to the broad genomic research community. Funding is for up to five years.

Closing date: 25 Jan 22

**Link to \*Research Professional** 

### Biomedical knowledgebase (U24 clinical trials not allowed)

#### **NIH: National Institute of General Medical Sciences**

This supports the extraction, accumulation, organisation, annotation and linking of growing bodies of information related to core

datasets. The maximum project period is five years.

Closing date: 25 Jan 22

Link to \*Research Professional

### Biomedical data repository (U24 – clinical trials not allowed)

#### **NIH: National Institute of General Medical Sciences**

This supports biomedical data repositories whose primary function is to ingest, archive, preserve, manage, distribute, and make accessible the data related to a particular system or systems. The

maximum project period is five years.

Closing date: 25 Jan 22



# Mechanism-focused research to promote adherence to healthful behaviours to prevent mild cognitive impairment and Alzheimer's disease and related dementias (R01 clinical trial optional)

### **NIH: National Institute on Aging**

This supports ancillary studies that address psychological and interpersonal mechanisms driving adherence to behaviour or lifestyle change relevant to the prevention of cognitive decline, mild cognitive impairment and Alzheimer's disease

and Alzheimer's disease-related dementias. The maximum project period is five years.

Closing date: 26 Jan 22

Link to \*Research Professional

### Research projects in cancer systems biology (U01 clinical trial optional)

#### **NIH: National Cancer Institute**

This supports collaborative research projects that use systems biology approaches to address challenges relating to cancer initiation, progression and treatment. Funding

is worth up to USD 400,000 per year over a maximum period of five years.

Closing date: 28 Jan 22

**Link to \*Research Professional** 

### Notice of special interest – administrative supplements for summer research experiences for students and science teachers

#### NIH: National Institute of Environmental Health Sciences

This is intended to introduce students and teachers to research in the environmental health sciences that would not otherwise be available to them through their regular course of study.

Closing date: 31 Jan 22

**Link to \*Research Professional** 

BRAIN initiative – biology and biophysics of neural stimulation and recording technologies (R01 clinical trial optional)

NIH: National Institute of Neurological Disorders and Stroke



This supports researchers in developing new and improved technologies to record from and control specified cell types and circuits to modulate and understand function in the central nervous

system. The maximum project period is five years.

Closing date: 01 Feb 22

**Link to \*Research Professional** 

## <u>Pilot projects increasing the impact of the NIH Centres for</u> <u>Advancing Research on Botanicals and Other Natural Products</u> (R03 clinical trials not allowed)

### **NIH: National Center for Complementary and Integrative Health**

This supports collaborative pilot research projects focused on potential effects relevant to human health of chemically complex natural products or the causal, molecular mechanisms underlying such effects.

Awards are worth up to USD 50,000 in direct costs per year for a maximum of two years.

Closing date: 01 Feb 22

**Link to \*Research Professional** 

Notice of special interest – administrative supplements to support addiction science and related neuroscience pilot research projects at NIMHD-funded research centres in minority institutions

### **NIH: National Institute on Minority Health and Health Disparities**

This provides administrative supplements to NIMHD research centers in minority institutions awards to support pilot research projects led by early-stage investigators focused on research on substance use, addiction, or

neuroscience. Each grant is worth up to USD 50,000 per year and has a maximum project period of two years.

Closing date: 01 Feb 22

Link to \*Research Professional

## Elucidating the effects of anti-retroviral therapy on neuronal function in the context of substance use dosorders and HIV (R01 clinical trials not allowed)

#### **NIH: National Institute on Drug Abuse**

This supports research into the effects of anti-retroviral therapy on

neuronal and glial structure and function, particularly when



occurring in a background of chronic exposure to addictive substances, including opioids, cocaine and other stimulants, cannabinoids and nicotine. The total budget is worth

USD 3 million to fund between eight and 10 awards.

Closing date: 02 Feb 22

Link to \*Research Professional

### Role of astrocytes in degeneration of the neurovascular unit in AD/ADRDs (R01 clinical trial not allowed)

### NIH: National Institute of Neurological Disorders and Stroke

This supports basic research on the mechanisms of reactive astrogliosis in degeneration of the neurovascular unit that contributes to cognitive impairment and dementia. Five

grants worth up to USD 500,000 are available for up to five years.

Closing date: 04 Feb 22

**Link to \*Research Professional** 

### <u>Dissemination and implementation research in health (R01 clinical trial optional)</u>

#### **NIH: National Cancer Institute**

This supports innovative approaches that aim to identify and develop strategies to disseminate and implement evidence-based practices into public health, clinical practice, and community settings. Application

budgets are not limited. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### **Bioengineering research grants (R01 clinical trial required)**

### NIH: National Institute of Biomedical Imaging and Bioengineering

These support collaborations between the life and physical sciences that apply a multidisciplinary bioengineering approach to the solution of a biomedical problem. Grants are for up to five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Bioengineering research partnerships (U01 clinical trial required)

NIH: National Institute of Biomedical Imaging and Bioengineering



These support bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important

biomedical problems. The maximum project period is five years.

Closing date: 05 Feb 22

Link to \*Research Professional

### Research project grant (parent R01 basic experimental studies with humans required)

### **NIH: National Eye Institute**

This supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the

investigators. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### NLM research grants in biomedical informatics and data science (R01 clinical trial optional)

#### **NIH: National Library of Medicine**

This supports innovative research and development in biomedical informatics and data science. Grants are worth up to USD 250,000 each per year over a maximum period of four years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### <u>Drug discovery for nervous system disorders (R01 clinical trials not allowed)</u>

#### NIH: National Institute of Neurological Disorders and Stroke

This supports the discovery of novel compounds for the prevention and treatment of nervous system

disorders. Funding is for up to five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### EXTENDED DEADLINE: Accelerating the pace of drug abuse research using existing data (R01 clinical trial optional)

**NIH: National Institute on Drug Abuse** 



This grant supports the innovative analysis of existing social science, behavioural, administrative and neuroimaging data to study the aetiology and epidemiology of drugusing behaviours and related disorders, prevention of drug use

and HIV and health service use. Grants are worth up to USD 499,999 per year over a maximum period of five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Alzheimer's drug development programme (U01 clinical trial optional)

### **NIH: National Institute on Aging**

This supports preclinical and early stage clinical development of small-molecule and biologic therapeutic agents that prevent Alzheimer's disease, slow its progression or treat its cognitive and behavioural

symptoms. Funding is worth up to USD 1 million per project per year for up to five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Research on autism spectrum disorders (R01 clinical trial optional)

#### NIH: National Institute of Mental Health

This supports research designed to elucidate the aetiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to autism spectrum disorders. Application budgets are not limited, but must

reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 22

Link to \*Research Professional

### NINDS exploratory clinical trials (U01 clinical trial required)

#### **NIH: National Institute of Neurological Disorders and Stroke**

This supports investigator-initiated exploratory clinical trials within the mission and research interests of the National Institute of Neurological Disorders and Stroke. Application budgets are not limited but must

reflect the actual needs of the project. The maximum project period is five years.

Closing date: 05 Feb 22



### Cellular and molecular biology of complex brain disorders (R01 clinical trial not allowed)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function.

The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### **NeuroNEXT clinical trials (U01 clinical trial optional)**

### NIH: National Institute of Neurological Disorders and Stroke

This supports exploratory clinical trials of investigational agents that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies or for

proof-of-mechanism clinical studies. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### <u>Discovery of in vivo chemical probes for the nervous system</u> (R01 clinical trial not allowed)

### NIH: National Institute of Neurological Disorders and Stroke

This supports research on in vivo chemical probes for novel brain targets. Projects may last up to four years.

Closing date: 05 Feb 22

Link to \*Research Professional

New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 (collab) clinical trial not allowed)

#### **NIH: National Institute of Neurological Disorders and Stroke**

This supports the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex

aetiologies identified through genome-wide association or sequencing studies. Funding is for up to five years.



Closing date: 05 Feb 22 <u>Link to \*Research Professional</u>

## New computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01 clinical trial not allowed)

### NIH: National Institute of Neurological Disorders and Stroke

This supports the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### <u>Clinical studies of mental illness (collaborative R01 clinical trial optional)</u>

### NIH: National Institute of Neurological Disorders and Stroke

This supports collaborative clinical studies that do not involve treatment development, efficacy or effectiveness trials. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

## Research projects to enhance applicability of mammalian models for translational research (R01 clinical trial not allowed)

#### **NIH: National Cancer Institute**

This supports research that aims to expand, improve or transform the utility of mammalian cancer and tumour models for translational research. Application budgets are limited to USD 450,000 in direct

costs per year for a maximum of five years.

Closing date: 05 Feb 22

Link to \*Research Professional

### Research on chronic overlapping pain conditions (R01)

NIH: National Institute of Neurological Disorders and Stroke



This supports epidemiological, clinical and translational research that will increase understanding of the presence of multiple chronic pain conditions in subjects with pain. Funding is for up to five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

## <u>Academic-industrial partnerships for translation of technologies for diagnosis and treatment (R01 clinical trial not allowed)</u>

### **NIH: National Cancer Institute**

This supports efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect,

prevent and manage disease. Grants are worth up to USD 499,000 each per year for a maximum duration of five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Achieving tissue robustness through harnessing immune system plasticity (R01 clinical trial not allowed)

#### **NIH: National Institute of Dental and Craniofacial Research**

This supports state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral and

craniofacial diseases. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### End-of-life and palliative needs of adolescents and young adults with serious illnesses (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This supports research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses.

Application budgets are not limited but need to reflect the actual needs

of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 22



## Late stage clinical trials for the spectrum of Alzheimer's disease and age-related cognitive decline (R01 clinical trial required)

#### **NIH: National Institute on Aging**

This supports the development and implementation of late stage clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease

spectrum from pre-symptomatic to more severe stages of disease. Funding is for up to five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

## Early-stage clinical trials for the spectrum of Alzheimer's disease and age-related cognitive decline (R01 clinical trial optional)

### **NIH: National Institute on Aging**

This supports the development and implementation of early-stage clinical trials of promising pharmacological and non-pharmacological interventions related to age-related cognitive decline and Alzheimer's disease.

Funding is for up to five years. The total budget for the fiscal year 2019 is USD 10 million, funding 10 to 15 grants.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### <u>Improving outcomes in cancer treatment-related</u> <u>cardiotoxicity (R01 clinical trial optional)</u>

#### **NIH: National Cancer Institute**

This supports collaborative projects that contribute to the identification and characterisation of patients at risk of developing cancer treatmentrelated cardiotoxicity. The maximum project period is five years.

Closing date: 05 Feb 22



# Development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and for pathophysiological studies of CNS disorders (R01 clinical trial optional)

### NIH: National Institute of Neurological Disorders and Stroke

This supports research on the development of novel radioligands for positron emission tomography or single photon emission computed tomography imaging in human brain, and that incorporate pilot or

clinical feasibility evaluation in preclinical studies. The maximum project period is four years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

## Programme to assess the rigour and reproducibility of extracellular vesicle-derived analytes for cancer detection (R01 clinical trial not allowed)

#### **NIH: National Cancer Institute**

This supports innovative research projects that focus on the isolation and characterisation of extracellular vesicles and their cargo for discovery of predictive biomarkers.

The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

## Translational bioinformatics approaches to advance drug repositioning and combination therapy development for Alzheimer's disease (R01 clinical trial optional)

#### **NIH: National Institute on Aging**

This enables data-driven drug repositioning and combination therapy for Alzheimer's disease and related dementias by developing computational methods and data resources or integrating computational approaches with

proof-of-concept efficacy studies in cell-based models, animal models or humans. The maximum project period is five years.

Closing date: 05 Feb 22



### Academic-industrial partnerships to translate and validate in vivo cancer imaging systems (R01 clinical trial optional)

#### **NIH: National Cancer Institute**

This supports research on methods or tools that address problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment or disease status for cancer or other disease. The maximum project period is five years.

Closing date: 05 Feb 22

Link to \*Research Professional

### <u>Perception and cognition research to inform cancer image</u> <u>perception (R01 clinical trial optional)</u>

#### **NIH: National Cancer Institute**

This supports research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology to improve the

accuracy of cancer detection and diagnosis. Funding is for five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

## <u>Cancer tissue engineering collaborative – enabling biomimetic tissue-engineered technologies for cancer research (R01 clinical trial optional)</u>

#### **NIH: National Cancer Institute**

This supports the development and characterisation of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Budgets are limited to USD 400,000

in direct costs per year for a maximum of five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

## Secondary analysis and integration of existing data to elucidate the genetic architecture of cancer risk and related outcomes (R01 clinical trial not allowed)

#### **NIH: National Cancer Institute**

This supports secondary data analysis and integration of existing datasets and database resources to elucidate the genetic architecture of cancer risk and related outcomes.



Grants are worth up to USD 350,000 each for year for up to five years.

Closing date: 05 Feb 22

Link to \*Research Professional

### Effectiveness trials for post-acute interventions and services to optimise longer-term outcomes (R01 clinical trial required)

### NIH: National Institute of Neurological Disorders and Stroke

This supports research projects that evaluate the effectiveness of service delivery interventions for the post-acute management of mental health conditions affecting youth, adults and older adults. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

## Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 clinical trial not allowed)

#### **NIH: National Cancer Institute**

This supports research in discovery and development of novel, small molecules for their potential use in studying disease treatment, and to generate new insight into the biology of relevant diseases and

processes. The maximum project period is four years.

Closing date: 05 Feb 22

Link to \*Research Professional

### <u>Understanding and modifying temporal dynamics of</u> coordinated neural activity (R01 clinical trial optional)

### NIH: National Institute of Neurological Disorders and Stroke

This supports research to lay the groundwork for developing systems-level neuroscience interventions into treatments for cognitive, affective or social deficits in psychiatric disorders. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 22



### Research project grant (parent R01 clinical trial not allowed)

#### **NIH: National Eye Institute**

This supports a discrete, specified and circumscribed project in areas representing the specific interests and competencies of the investigators. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Alzheimer's clinical trials consortium clinical trials (R01 clinical trial required)

### **NIH: National Institute on Aging**

This supports the development and implementation of phase Ib to III clinical trials of pharmacological and non-pharmacological interventions that may prevent, delay, or treat Alzheimer's disease. Application budgets are not limited but need to

reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Cancer prevention and control clinical trials grant programme (R01 clinical trial required)

#### **NIH: National Cancer Institute**

This supports investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, prevention, healthcare delivery, quality of life or

survivorship related to cancer. The maximum project period is five years.

Closing date: 05 Feb 22

Link to \*Research Professional

### Investigator-initiated early phase clinical trials for cancer treatment and diagnosis (R01 clinical trial required)

#### **NIH: National Cancer Institute**

This supports projects that implement early phase investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions.

Application budgets are limited to

less than USD 500,000 in direct costs per year. The maximum project period is five years.

Closing date: 05 Feb 22



### Innovative screening approaches and therapies for screenable disorders in new-borns (R01 clinical trial optional)

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research relevant to the development of novel screening approaches or therapeutic interventions for potentially fatal or disabling conditions that have been identified through new-born screening, as well as for high priority genetic conditions where screening may be possible in the near future. Funding is for five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Innovative mental health services research not involving clinical trials (R01)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. Funding may last for up to five years.

Closing date: 05 Feb 22

Link to \*Research Professional

### Investigator-initiated research in computational genomics and data science (R01 clinical trial not allowed)

#### NIH: National Human Genome Research Institute

This supports fundamental genomics research developing innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to

the biomedical genomics community. Grants are worth up to USD 500,000 for up to five years.

Closing date: 05 Feb 22



### Novel mechanism research on neuropsychiatric symptoms in Alzheimer's dementia (R01 clinical trial optional)

#### **NIH: National Institute of Neurological Disorders and Stroke**

This supports studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms in persons with Alzheimer's disease or Alzheimer's disease-related dementias. Funding is for up to five years.

Closing date: 05 Feb 22

Link to \*Research Professional

## <u>Development and optimisation of tasks and measures for functional domains of behaviour (R01 clinical trial not allowed)</u>

### NIH: National Institute of Neurological Disorders and Stroke

This supports the development and optimisation of tasks or measures for constructs related to functional aspects of behaviour or cognitive or affective processes, for use in laboratory or population-based

studies, clinical trial outcomes or related research. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Neuromodulation and neurostimulation device development for mental health applications (R01 clinical trial not allowed)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports the development of the next generation of brain stimulation devices for treating mental health disorders. The maximum project period is five years.

Closing date: 05 Feb 22

Link to \*Research Professional

### Biobehavioural basis of chronic pain (R01 clinical trial optional)

#### **NIH: National Institute of Nursing Research**

This supports studies on the biobehavioural basis of chronic pain with a focus on the individual phenotype, genotype, and other omic-type assessments and the

associated sensory and emotional components that underpin the individual's chronic pain experience. The maximum project period is five years.



Closing date: 05 Feb 22 <u>Link to \*Research Professional</u>

### Applying a biopsychosocial perspective to self-management of chronic pain (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This supports the applications of a biopsychosocial perspective to selfmanagement of chronic pain. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Addressing caregiver symptoms through technological tools (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This supports the development and testing of tools to address symptoms in caregivers, regardless of patient symptoms or conditions. The project may last up to five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Basic neurodevelopmental biology of circuits and behaviour (R01 clinical trial not allowed)

#### **NIH: National Institute of Neurological Disorders and Stroke**

This supports research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviours across development in rodents and non-human primates.

Application budgets are limited to USD 500,000 in direct costs per year for up to five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

## Building in vivo preclinical assays of circuit engagement for application in therapeutic development (R01 clinical trial not allowed)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports the identification, in animals, of in vivo

neurophysiological and behavioural measures for use as assays in the



early screening phase of treatment development. Grants may last up to five years. Closing date: 05 Feb 22

Link to \*Research Professional

### Advancing research in augmentative and alternative communication (R01 clinical trial optional)

#### NIH: National Institute on Deafness and other Communication Disorders

This supports research on augmentative and alternative communication to advance scientific knowledge in the evaluation and treatment of individuals with complex communication needs or

with severe speech and physical impairments. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### End-of-life and palliative care approaches to advanced signs and symptoms (R01 clinical trial optional)

#### **NIH: National Institute of Nursing Research**

This supports the examination of the multi-dimentional foundation, experiences and management of complex, advanced signs and

symptoms at the end of life. The project may last up to five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Strategies to provide culturally tailored palliative and end-oflife care for seriously ill American Indian and Alaska Native individuals (R01 clinical trial optional)

#### **NIH: National Institute of Nursing Research**

This supports research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care for American Indian or Alaska Native individuals with advanced illness

and their families and communities. Funding is for five years.

Closing date: 05 Feb 22



### <u>Processing and presentation of non-conventional MHC ligands</u> (R01 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports the determination of antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptiic ligands and of the contribution of these unique antigenic ligands to

protective immune responses. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### <u>Telomeres in wellness and disease – a biobehavioural</u> approach (R01 clinical trial optional)

### **NIH: National Institute of Nursing Research**

This aims to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioural programmes of research.

Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 22

Link to \*Research Professional

### Accelerating malaria vaccine discovery (R01 clinical trial not allowed)

### **NIH: National Institute of Allergy and Infectious Diseases**

This supports early-phase translational research that will generate new vaccine candidates suitable for further downstream development and clinical evaluation.

The maximum project period is five years

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Advancing development of rapid fungal diagnostics (R01 clinical trial not allowed)

### **NIH: National Institute of Allergy and Infectious Diseases**

This supports the development of rapid, sensitive, specific, simple and cost-effective diagnostics for primary healthcare settings. The

maximum project period is five years.



Closing date: 05 Feb 22 <u>Link to \*Research Professional</u>

## Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis and other select endemic fungal infections (R01 clinical trial not allowed)

### **NIH: National Institute of Allergy and Infectious Diseases**

This supports research that contributes to the overall understanding of coccidioidomycosis and other select endemic fungal diseases including histoplasmosis and blastomycosis.

The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Molecular and genetic characterisation of inborn errors of immunity (R01 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This aims to advance the experimental validation and functional characterisation of genetic variants in coding or noncoding genomic regions that result in inborn errors of immunity or primary immunodeficiency diseases.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

## Control of sexually transmitted infections through a comprehensive understanding of the natural history of infection (R01 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports research to advance the understanding of the natural history of infection for gonorrhoea, syphilis and chlamydia. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 22



### Emotion regulation, ageing and mental disorder (R01 clinical trial not allowed)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults. The maximum project period is five vears.

Closing date: 05 Feb 22

Link to \*Research Professional

### Bioengineering research grants (R01 clinical trial not allowed)

### NIH: National Institute of Biomedical Imaging and Bioengineering

These support collaborations between the life and physical sciences that apply a multidisciplinary bioengineering approach to the solution of a biomedical problem. Grants are for up to five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Bioengineering research partnerships (U01 clinical trial not allowed)

#### NIH: National Institute of Biomedical Imaging and Bioengineering

These support bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important

biomedical problems. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

## Accelerating the pace of child health research using existing data from the adolescent brain cognitive development study (R01 clinical trial not allowed)

#### **NIH: National Institute on Drug Abuse**

This supports the analysis of public data to increase knowledge of adolescent health and development. Grants are worth up to USD 250,000

each per year for a maximum period of five years.

Closing date: 05 Feb 22



### **Biology of bladder cancer (R01 clinical trial optional)**

#### **NIH: National Cancer Institute**

This supports research into the biology and underlying molecular mechanisms driving initiation, progression and malignancy of bladder cancer. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

## <u>Limited competition – additional sequencing for the</u> <u>Alzheimer's disease sequencing project (U01 clinical trial not allowed)</u>

### **NIH: National Institute on Aging**

This supports sample acquisition, genome-wide association studies, whole genome sequencing, quality control checking, variant calling and data calling that will support the generation of data for the Alzheimer's disease sequencing

project follow-up study. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Cognitive systems analysis of Alzheimer's disease genetic and phenotypic data (U01 clinical trial not allowed)

#### **NIH: National Institute on Aging**

This supports the development of fast and efficient cognitive systems approaches to identify changes in Alzheimer's disease genetic architecture that increase risk of and protection against the disease. The

maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Multisite clinical trial implementation grant (R01 clinical trial required)

### **NIH: National Institute on Aging**

This supports the implementation of investigator-initiated multisite interventional clinical trials of all phases to identify treatments and

preventative interventions for diseases and conditions associated with ageing.



Closing date: 05 Feb 22 <u>Link to \*Research Professional</u>

### <u>Clinical characterisation of cancer therapy-induced adverse</u> <u>sequelae and mechanism-based interventional strategies (R01</u> clinical trial optional)

#### **NIH: National Cancer Institute**

This supports collaborative research projects that address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed

posttreatment effects. The maximum project period is five years.

Closing date: 05 Feb 22

Link to \*Research Professional

Utilising invasive recording and stimulating opportunities in humans to advance neural circuitry understanding of mental health disorders (R01 clinical trial optional)

### NIH: National Institute of Neurological Disorders and Stroke

This supports researchers in pursuing invasive neural recording studies focused on mental healthrelevant questions. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

Development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and for pathophysiological studies of central nervous system disorders (R01 clinical trial not allowed)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports the preclinical development of novel radioligands for positron emission tomography or single photon emission computed tomography imaging in rodent and nonhuman primate brain and incorporation of pilot or clinical

feasibility evaluation in preclinical studies. Grants are worth up to USD 275,000 each for up to three years.

Closing date: 05 Feb 22



### <u>Transcriptomic, epigenomic, regulatory RNA or functional</u> genomic research in substance use disorders

### **NIH: National Institute on Drug Abuse**

This supports research examining transcriptomic, genomic, epigenomic, regulatory RNA, nuclear organisation or functional genomics to better understand substance use disorder-related biological

processes. The maximum project period is five years.

Closing date: 05 Feb 22

Link to \*Research Professional

### Research on myalgic encephalomyelitis/chronic fatigue syndrome (R01 clinical trials not allowed)

### NIH: National Institute of Neurological Disorders and Stroke

This supports research that examines the aetiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitus/chronic fatigue syndrome in diverse groups and

across the lifespan. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Research project grant (parent R01 clinical trial required)

### **NIH: National Eye Institute**

This supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the

investigators. The maximum project period is five years.

Closing date: 05 Feb 22

Link to \*Research Professional

## Behavioural tasks targeting brain systems relevant to anhedonia (R01 basic experimental studies with humans required)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports research to develop task-based behavioural measures shown to engage brain systems relevant to anhedonia using neuroimaging or other brain measures with similar spatial resolution.

Closing date: 05 Feb 22



### Notice of special interest – simulation modelling and systems science to address health disparities

#### **NIH: National Institute on Minority Health and Health Disparities**

This supports investigative and collaborative research focused on developing and evaluating simulation modelling and systems science to understand and address

minority health and health disparities.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Notice of special interest – palliative care in heart, lung, blood and sleep diseases

#### NIH: National Heart, Lung and Blood Institute

This supports research focused on palliative care in patients with heart, lung, blood and sleep (HLBS) diseases across the lifespan, with a focus on how to better integrate and implement palliative care into patient management.

Closing date: 05 Feb 22

Link to \*Research Professional

## Notice of special interest – the influence of host resilience on heterogeneity of acute respiratory distress syndrome/acute lung injury

#### NIH: National Heart, Lung and Blood Institute

This supports research into the factors and molecular mechanisms that address the heterogeneity of

lung disease dictated by the host resilience.

Closing date: 05 Feb 22

Link to \*Research Professional

### Notice of special interest – integrative omics analysis of NHLBI TOPMed data (parent R01 clinical trial not allowed)

#### NIH: National Heart, Lung and Blood Institute

This supports analyses that utilise existing omics data generated within the framework of the trans-omics for precision medicine programme to uncover the molecular mechanisms



driving heart, lung, blood and sleep diseases.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Mood and psychosis symptoms during the menopause transition (R01 clinical trial optional)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports the advancement of mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition.

The maximum project period is 5 years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Notice of special interest – advances in research for the treatment, services and recovery of alcohol use disorder

#### **National Institute on Alcohol Abuse and Alcoholism**

This supports research on alcohol use disorder treatment and sustaining recovery.

Closing date: 05 Feb 22

Link to \*Research Professional

## Notice of special interest – research to address vaccine hesitancy, uptake and implementation among populations that experience health disparities

#### **NIH: National Institute on Minority Health and Health Disparities**

This supports research projects that evaluate strategies to facilitate vaccination uptake in clinical and community contexts, and address the barriers to increasing reach, access and uptake of vaccinations

among health disparity populations at high risk and likely to experience vaccine hesitancy.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

Notice of special interest – leveraging real-world imaging data for artificial intelligence-based modelling and early detection of abdominal cancers

**NIH: National Cancer Institute** 



This supports the secondary use of real-world data for artificial intelligence-based predictive modelling with the ultimate goal of

improving early detection and risk assessment for abdominal cancers.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Natural history of disorders screenable in the newborn period (R01 clinical trial optional)

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports studies that leads to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. Grants are tenable for up to five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

## <u>Academic-industrial partnerships for translation of technologies for diagnosis and treatment (R01 - clinical trial optional)</u>

#### **NIH: National Cancer Institute**

This supports efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect,

prevent and manage disease. Grants are worth up to USD 499,000 each per year for a maximum duration of five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Screening and functional validation of human birth defects genomic variants (R01 clinical trial not allowed)

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This seeks to promote the screening, functional validation and characterisation of birth defects-associated genetic variants identified through public facing databases and individual efforts

using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. Grants are worth up to USD 499,999 direct costs per year over five years.



Closing date: 05 Feb 22 <u>Link to \*Research Professional</u>

### <u>Dyadic interpersonal processes and biopsychosocial outcomes</u> (R01 clinical trials not allowed)

#### **NIH: National Institutes of Health**

This supports basic and methodological research projects that illuminate or measure independent and interdependent health-related effects within dyads across relationships and settings. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### <u>Paediatric immune system – ontogeny and development (R01 clinical trial not allowed)</u>

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This aims to correlate immune system in general and development patterns in particular, between two or more age groups, and further understand the impact of infectious diseases, microbiome and environmental factors on the

ontogeny and development of the pediatric immune system. Grants are worth up to USD 400,000 per year over four years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Notice of special interest – immune responses to arthropod feeding on vertebrate hosts

#### **NIH: National Institute of Allergy and Infectious Diseases**

This aims to improve the understanding of the immunologic events in the vertebrate host that occur at the bite site and systemically during and after feeding

by hematophagous and ectoparasitic arthropods.

Closing date: 05 Feb 22



### Basic research in cancer health disparities (R01 clinical trial not allowed)

### **NIH: National Cancer Institute**

This supports basic, mechanistic research into the biological and genetic causes of cancer health disparities that can be carried out in a short period of time with limited

resources. Funding may last for up to five years.

Closing date: 05 Feb 22

Link to \*Research Professional

### Notice of special interest - somatic cell gene editing therapies to improve transplantation outcomes

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports research that applies somatic cell gene editing approaches to improve graft survival and outcomes for recipients of allogenic solid organ, pancreatic islet, or vascularized composite allograft

transplants in animal models or human tissues or organs excluded from clinical use.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Clinical trial readiness for functional neurological disorders (U01 clinical trial optional)

### NIH: National Institute of Neurological Disorders and Stroke

This supports prospective clinical projects that address critical needs for clinical trial readiness in functional neurological disorders.

The maximum project period is five years.

Closing date: 05 Feb 22

**Link to \*Research Professional** 

### Modulating human microbiome function to enhance immune responses against cancer (R01 clinical trial not allowed)

#### **NIH: National Cancer Institute**

This supports basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumour immune responses, and to identify potential novel molecular targets for cancer prevention strategies. The maximum project period is 5 years.

Closing date: 05 Feb 22



### Ethical issues in translational science research (R01 clinical trial optional)

### **NIH: National Center for Advancing Translational Sciences**

This supports research on ethical issues in translational science research. Grants are worth up to USD 300,000 each in direct costs per

year for a maximum period of four years.

Closing date: 08 Feb 22

**Link to \*Research Professional** 

### Identification and characterisation of persistence mechanisms of select protozoan pathogens (R01 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports research that expands our understanding of protozoan parasite persistence mechanisms and provide research tools and strategies to enable identification and credentialing of novel treatments for persistent protozoan pathogens. The total budget is USD 4,500,000 to fund up to nine awards.

Closing date: 08 Feb 22

**Link to \*Research Professional** 

### NINDS efficacy clinical trials (UG3/UH3 clinical trial required)

#### **NIH: National Institute of Neurological Disorders and Stroke**

This supports investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke. Application budgets are not limited, but need to reflect the actual needs of the project. The

maximum project period is five years.

Closing date: 09 Feb 22

Link to \*Research Professional

## Blueprint neurotherapeutics network – small molecule drug discovery and development for disorders of the nervous system (UG3/UH3 clinical trial optional)

### NIH: National Institute of Neurological Disorders and Stroke

This supports neuroscience investigators seeking to advance their small molecule drug discovery

and development projects into the clinic. The maximum project period



is one year in the UG3 phase and four years in the UH3 phase.

Closing date: 09 Feb 22

Link to \*Research Professional

### <u>Blueprint neurotherapeutics network – biologic-based drug</u> <u>discovery and development for disorders of the nervous</u> system (UG3/UH3 clinical trial optional)

### **NIH: National Institute of Neurological Disorders and Stroke**

This supports preclinical discovery and development of potential therapeutic biotechnology products and biologics, gene-based therapies, cell therapies and novel emerging therapies. The maximum project period is five years.

Closing date: 09 Feb 22

**Link to \*Research Professional** 

### Pharmacokinetics and pharmacodynamics of Δ9tetrahydrocannabinol in cannabis and cannabis products (R01 clinical trial optional)

### **NIH: National Institute on Drug Abuse**

This supports human and animal research on the pharmacokinetic and pharmacodynamic effects of  $\Delta 9$ -tetrahydrocannabinol present in cannabis and cannabis products.

Grants are worth up to USD 500,000 per year for up to five years.

Closing date: 09 Feb 22

Link to \*Research Professional

### Pharmacokinetics and pharmacodynamics of Δ9tetrahydrocannabinol in cannabis and cannabis products (R21 clinical trial optional)

#### **NIH: National Institute on Drug Abuse**

This supports human and animal research on the pharmacokinetic and pharmacodynamic effects of  $\Delta 9$ -tetrahydrocannabinol present in cannabis and cannabis products.

Grants are worth up to USD 275,000 for up to two years.

Closing date: 09 Feb 22



### Pragmatic trials for dementia care and caregiver support (R61/R33 clinical trial required)

### **NIH: National Institute on Aging**

This supports pragmatic trials for dementia care that are designed to address practical comparative questions faced by Alzheimer's disease and Alzheimer's-related dementia patients, clinicians, and caregivers. Grants for the R61

planning phase are worth up to USD 500,000 each for up to two years, and for the R33 phase over USD 500,000 each for up to four years.

Closing date: 10 Feb 22

Link to \*Research Professional

### <u>Dementia care and caregiver support intervention research</u> (R01 clinical trial required)

### **NIH: National Institute on Aging**

This supports mechanism-focused dementia care and caregiver support intervention development research to address the care needs and promote the health, function, and well-being of persons with Alzheimer's disease and Alzheimer's

disease-related dementias and of those providing their care. The maximum project period is five years.

Closing date: 10 Feb 22

**Link to \*Research Professional** 

## Utilising the PLCO biospecimens resource to bridge gaps in cancer aetiology and early-detection research (U01 clinical trial not allowed)

#### **NIH: National Cancer Institute**

This supports research in cancer aetiology and early-detection biomarkers, using the biorepository resources of the National Caner Institute-sponsored prostate, lung, colorectal and ovarian cancer

screening trial. Application budgets are not limited. The maximum project period is five years.

Closing date: 11 Feb 22

**Link to \*Research Professional** 

### <u>Single-site investigator-initiated clinical trials (R61/R33 clinical trial required)</u>

NIH: National Heart, Lung and Blood Institute



This supports the development and implementation investigator-initiated single-site clinical trials relevant to the research mission of the National Heart, Lung and Blood

Institute. The maximum project period is five years.

Closing date: 11 Feb 22

**Link to \*Research Professional** 

## <u>Clinical coordinating centre for multi-site investigator-initiated clinical trials (collaborative UG3/UH3 clinical trial required)</u>

### NIH: National Heart, Lung and Blood Institute

This supports the development and implementation of a clinical coordinating centre for investigator-initiated multi-site clinical trials that are relevant to the research mission of the National Heart, Lung and Blood Institute. Application budgets

are not limited but need to reflect the actual needs of the proposed project.

Closing date: 11 Feb 22

**Link to \*Research Professional** 

### Data coordinating centre for multi-site investigator-initiated clinical trials (collaborative U24 clinical trial required)

#### NIH: National Heart, Lung and Blood Institute

This supports the implementation of a collaborating data coordinating centre for investigator-initiated multi-site clinical trials that are relevant to the research mission of the National Heart, Lung, and Blood Institute. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 11 Feb 22

**Link to \*Research Professional** 

### HIV/AIDS high priority drug abuse research (R01 clinical trial optional)

#### **NIH: National Institute on Drug Abuse**

This supports high priority research at the intersection of HIV and substance use. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 15 Feb 22



### **Tobacco regulatory science (R01 clinical trial optional)**

#### **NIH: National Cancer Institute**

This supports biomedical and behavioural research that provides scientific data to inform regulation of tobacco products to protect public health. Grants are worth up to USD 500,000 each in direct costs per year

for a maximum project period of three years.

Closing date: 15 Feb 22

**Link to \*Research Professional** 

## HEAL initiative – non-addictive analgesic therapeutics development to treat pain (UG3/UH3 clinical trial not allowed)

### NIH: National Institute of Neurological Disorders and Stroke

This supports preclinical optimisation and development of safe, effective and non-addictive small molecule and biologic therapeutics to treat pain. The

maximum project period is five years.

Closing date: 15 Feb 22

**Link to \*Research Professional** 

## <u>Pilot projects increasing the impact of the NIH Centres for</u> <u>Advancing Research on Botanicals and Other Natural Products</u> (R03 clinical trials not allowed): AIDS-related

### **NIH: National Center for Complementary and Integrative Health**

This supports AIDS-related collaborative pilot research projects focused on potential effects relevant to human health of chemically complex natural products or the causal, molecular mechanisms underlying such effects. Awards are

worth up to USD 50,000 in direct costs per year for a maximum of two years.

Closing date: 15 Feb 22

Link to \*Research Professional

### NEI research grant for vision related secondary data analysis (R21 clinical trial not allowed)

### **NIH: National Eye Institute**

This supports vision-related secondary data analyses utilising existing database resources. Grants

are worth up to to USD 275,000 for a maximum period of two years.



Closing date: 16 Feb 22 <u>Link to \*Research Professional</u>

### <u>Imaging – science track award for research transition (R03</u> clinical trial optional)

#### **NIH: National Institute on Drug Abuse**

This facilitates the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programmes, to

enable them to conduct small proof of concept studies. Awards are worth up to USD 150,000 each for a maximum period of one year.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

### Exploratory or developmental research grant programme (parent R21 clinical trial not allowed)

#### **NIH: National Eye Institute**

This supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Application budgets are limited to USD 275,000 for a two-year period,

with no more than USD 200,000 in any single year.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## Small research grants for oral health data analysis and statistical methodology development (R03 clinical trial not allowed)

#### NIH: National Institute of Dental and Craniofacial Research

This supports research projects that involve secondary data analyses of existing oral or craniofacial database resources, or the development of needed statistical methodology for analysing oral and craniofacial data using existing oral or craniofacial

databases. Funding is worth up to USD 200,000 per project over two years.

Closing date: 16 Feb 22



### <u>Dissemination and implementation research in health (R21 clinical trial optional)</u>

#### **NIH: National Cancer Institute**

This supports innovative approaches to identifying and developing strategies to disseminate and implement evidence-based practices into public public health, clinical practice and community settings.

Grants are worth up to USD 275,000 each for two years.

Closing date: 16 Feb 22

Link to \*Research Professional

### Small research grant programme (parent R03 clinical trial not allowed)

### **NIH: National Institute of Nursing Research**

This supports small research projects that can be carried out in a short period of time with limited resources. Awards are worth up to

USD 50,000 in direct costs per year for up to two years.

Closing date: 16 Feb 22

Link to \*Research Professional

### Research on autism spectrum disorders (R03 clinical trial optional)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports research designed to elucidate the aetiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to autism spectrum disorders. Direct costs are

limited to USD 100,000 over a twoyear project period.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

### Research on autism spectrum disorders (R21 clinical trial optional)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports research designed to elucidate the aetiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to autism

spectrum disorders. Application budgets are limited to USD 275,000 for a maximum period of two years.

Closing date: 16 Feb 22



## **Exploratory/developmental bioengineering research grants** (R21 clinical trial optional)

#### **NIH: National Cancer Institute**

This supports the demonstration of feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical or clinical

research, clinical care delivery or accessibility. Direct costs are limited to USD 275,000 over a two-year period.

Closing date: 16 Feb 22

Link to \*Research Professional

## <u>Drug discovery for nervous system disorders (R21 clinical trial</u> not allowed)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports the discovery of novel compounds for the prevention and treatment of nervous system

disorders. Grants are worth up to USD 275,000 each over two years.

Closing date: 16 Feb 22

Link to \*Research Professional

# National Institute of Dental and Craniofacial Research small grant programme for new investigators (R03 clinical trial not allowed)

#### **NIH: National Institute of Dental and Craniofacial Research**

This supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. Grants are

worth up to USD 200,000 over a maximum period of two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

<u>Pilot and feasibility studies in preparation for drug and alcohol</u> <u>abuse prevention trials (R34 clinical trial optional)</u>

**NIH: National Institute on Drug Abuse** 



This supports research that provides intervention pilot or feasibility data serving as a prerequisite for subsequent applications for larger scale drug or alcohol abuse prevention or drug- or alcohol-

related HIV prevention intervention studies. Grants are worth up to USD 450,000 each over three years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## <u>Pilot health services and economic research on the treatment</u> of drug, alcohol and tobacco abuse (R34 clinical trial optional)

#### **NIH: National Institute on Drug Abuse**

This encourages pilot and preliminary research in preparation for larger-scale services research

effectiveness trials. Grants are worth up to USD 450,000 over three years.

Closing date: 16 Feb 22

Link to \*Research Professional

## <u>Dissemination and implementation research in health (R03 clinical trial not allowed)</u>

#### **NIH: National Cancer Institute**

This supports innovative approaches to identifying, understanding and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies and

guidelines. Grants are worth up to USD 50,000 per year for a maximum period of two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## Research on chronic overlapping pain conditions (R21 clinical trial not allowed)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain

conditions in people with pain. The combined budget for direct costs for the two year project period may not exceed USD 275,000.

Closing date: 16 Feb 22



## Achieving tissue robustness through harnessing immune system plasticity (R21 clinical trial not allowed)

#### **NIH: National Institute of Dental and Craniofacial Research**

This supports state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral and craniofacial diseases. Grants are

worth up to USD 275,000 each over a maximum project period of two years.

Closing date: 16 Feb 22

Link to \*Research Professional

## <u>Pilot services research grants not involving clinical trials (R34</u> clinical trial not allowed)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports pilot research consistent with the institute's priorities for services research studies that are not immediate precursors to the development and testing of services interventions.

Funding is worth up to USD 450,000 per project over three years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## End-of-life and palliative needs of adolescents and young adults with serious illnesses (R21 clinical trial optional)

#### **NIH: National Institute of Nursing Research**

This aims to foster research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses. Direct

costs are limited to USD 275,000 over a two-year period.

Closing date: 16 Feb 22

Link to \*Research Professional

## Clinical trial readiness for rare neurological and neuromuscular diseases (U01 clinical trial not allowed)

#### **NIH: National Institute of Neurological Disorders and Stroke**

This supports clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. Grants are worth up to USD 650,000 each per year over five years.

Closing date: 16 Feb 22



## Improving outcomes in cancer treatment-related cardiotoxicity (R21 clinical trial optional)

#### **NIH: National Cancer Institute**

This supports collaborative projects that contribute to the identification and characterisation of patients at risk of developing cancer treatment-related cardiotoxicity. Grants are worth up to USD 275,000 each over

a two-year period, with no more than USD 200,000 allowed in any single year.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## Small research grants for analyses of Gabriella Miller Kids First paediatric research data (R03 clinical trial not allowed)

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports meritorious small research projects that involve analyses of datasets that are part of the Kids First programme, and projects that develop approaches, tools or algorithms to support or

enhance analyses of these data. Grants are worth up to USD 200,000 each over two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

#### <u>Perception and cognition research to inform cancer image</u> <u>interpretation (R21 clinical trial optional)</u>

#### **NIH: National Cancer Institute**

This supports research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and

diagnosis. Grants are worth up to USD 275,000 each for two years.

Closing date: 16 Feb 22



# Secondary analysis and integration of existing data to elucidate the genetic architecture of cancer risk and related outcomes (R21 clinical trials not allowed)

#### **NIH: National Cancer Institute**

This supports secondary data analysis and integration of existing datasets and database resources, with the ultimate aim of elucidating the genetic architecture of cancer risk and related outcomes. Grants are worth up to USD 275,000 over two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

# <u>Pilot effectiveness trials for post-acute interventions and services to optimise longer-term outcomes (R34 clinical trial required)</u>

#### NIH: National Institute of Neurological Disorders and Stroke

This supports pilot effectiveness projects that evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the

stage of illness in terms of both their focus. Direct costs are limited to USD 450,000 over a period of up to three years.

Closing date: 16 Feb 22

Link to \*Research Professional

#### <u>Discovery of cell-based chemical probes for novel brain</u> <u>targets (R21 clinical trial not allowed)</u>

#### **NIH: National Institute of Mental Health**

This supports investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel

brain targets. Grants are worth up to USD 275,000 over a two-year period.

Closing date: 16 Feb 22

Link to \*Research Professional

## <u>Understanding and modifying temporal dynamics of</u> coordinated neural activity (R21 clinical trial optional)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports projects that test whether modifying

electrophysiological patterns during behaviour can improve cognitive,



affective or social processing. The combined budget for direct costs for the two-year project period may not exceed USD 275,000.

Closing date: 16 Feb 22

Link to \*Research Professional

## **Exploratory or developmental research grant programme** (parent R21 clinical trial required)

#### **NIH: National Eye Institute**

This supports exploratory and developmental research projects in their early and conceptual stages. Awards are worth up to USD

275,000 in direct costs for up to two years.

Closing date: 16 Feb 22

Link to \*Research Professional

#### <u>Joint NINDS/NIMH exploratory neuroscience research grant</u> (R21 clinical trial optional)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports exploratory and innovative research projects, which fall within the mission of the National Institute of Neurological Disorders and Stroke and the National Institute of Mental Health.

Grants are worth up to USD 275,000 for two years.

Closing date: 16 Feb 22

Link to \*Research Professional

#### NICHD small grant programme (R03 clinical trial optional)

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports small research projects that can be carried out in a short period of time with limited resources. Application budgets are

limited to USD 50,000 in direct costs per year for two years.

Closing date: 16 Feb 22



#### <u>Pilot studies of biological, behavioural and social mechanisms</u> <u>contributing to HIV pathogenesis within the mission of the</u> NIDDK (R21 clinical trial not allowed)

#### NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports research projects examining HIV infection, persistence, and comorbidities relevant to the the study of diabetes and other endocrine and metabolic diseases, digestive diseases, nutritional disorders, obesity, and

kidney, urologic and haematologic diseases. Grants are worth up to USD 275,000 each for up to two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## NIDA small research grant programme (R03 clinical trial required)

#### **NIH: National Institute on Drug Abuse**

This supports small clinical trials that can be carried out in a short period of time with limited resources. Grants are worth up to USD 50,000 each per year for up to two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## Mechanisms of alcohol tolerance (R21/R33 clinical trial not allowed)

#### **National Institute on Alcohol Abuse and Alcoholism**

This supports the study of sensitivity and tolerance mechanisms underlying the development of alcohol use disorders. The award is worth up to USD 1.75 million for up to five years.

Closing date: 16 Feb 22

Link to \*Research Professional

## Innovative screening approaches and therapies for screenable disorders in new-borns (R03 clinical trial optional)

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research relevant to the development of novel screening approaches or therapeutic interventions for potentially fatal or disabling conditions that have been identified through new-born



screening, as well as for high priority genetic conditions where screening may be possible in the near future. Grants are worth up to USD 50,000 each per year for up to two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## <u>Innovative screening approaches and therapies for screenable</u> disorders in new-borns (R21 clinical trial optional)

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research relevant to the development of novel screening approaches or therapeutic interventions for potentially fatal or disabling conditions that have been identified through new-born screening, as well as for high priority genetic conditions where screening may be possible in the near future. Grants are worth up to USD 275,000 each over two years.

Closing date: 16 Feb 22

Link to \*Research Professional

# Small research grants for establishing basic science-clinical collaborations to understand structural birth defects (R03 clinical trial not allowed)

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

These promote the initial establishment of basic science-clinical collaboration by providing small grants to teams of basic scientists, physician scientists or clinicians. Grants are worth up to

USD 75,000 per year for up to two years.

Closing date: 16 Feb 22

Link to \*Research Professional

## Investigator-initiated research in computational genomics and data science (R21 clinical trial not allowed)

#### NIH: National Human Genome Research Institute

This supports fundamental genomics research developing innovative analytical methodologies and approaches, early-stage development of tools and software,

and refinement or hardening of software and tools of high value to the biomedical genomics community. Direct costs are limited



to USD 275,000 over a two-year project period.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

# Alcohol and other drug interactions – unintentional injuries and overdoses – epidemiology and prevention (R03 clinical trial optional)

#### **National Institute on Alcohol Abuse and Alcoholism**

This supports research on how alcohol and other illicit drugs or illicitly-used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent or reduce simultaneous use of alcohol

or drugs singly or in combination. Grants are each worth up to USD 50,000 per year for a maximum period of two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## Novel mechanism research on neuropsychiatric symptoms in Alzheimer's dementia (R21 clinical trial optional)

#### **NIH: National Institute of Neurological Disorders and Stroke**

This supports studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms in people with Alzheimer's disease or Alzheimer's disease-related dementias. Grants are worth up to USD 275,000 each for up to two years.

Closing date: 16 Feb 22

Link to \*Research Professional

## Applying a biopsychosocial perspective to self-management of chronic pain (R21 clinical trial optional)

#### **NIH: National Institute of Nursing Research**

This supports the applications of a biopsychosocial perspective to selfmanagement of chronic pain. Grants are worth up to USD 275,000 for two years.

Closing date: 16 Feb 22



## Biobehavioural basis of chronic pain (R21 clinical trial optional)

#### **NIH: National Institute of Nursing Research**

This supports research that focuses on the individual phenotype, genotype and other omic-type assessments and the associated sensory and emotional components that underpin the individual's

chronic pain experience. Grants are worth up to USD 275,000 each over a maximum period of two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## Fc-dependent mechanisms of antibody-mediated killing (R21 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports research that aims to improve the understanding of Fcdependent, antibody-mediated killing of pathogen-infected or otherwise dysregulated host cells. Grants are each worth up to USD

275,000 over a maximum of two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## Addressing caregiver symptoms through technological tools (R21 clinical trial optional)

#### **NIH: National Institute of Nursing Research**

This supports the development and testing of tools to address symptoms in caregivers, regardless of patient symptoms or conditions. Grants are

worth up to USD 275,000 each over a maximum period of two years.

Closing date: 16 Feb 22

Link to \*Research Professional

## Basic neurodevelopmental biology of brain circuits and behaviour (R21 clinical trial not allowed)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports research on the dynamic and mechanistic links between the maturation of brain circuits and behaviours across development in rodents and nonhuman primates. Grants are worth up to USD 275,000 each for a maximum period of two years.

Closing date: 16 Feb 22



## Advancing research in augmentative and alternative communication (R21 clinical trial optional)

#### NIH: National Institute on Deafness and other Communication Disorders

This supports research on augmentative and alternative communication to advance scientific knowledge in the evaluation and treatment of individuals with complex communication needs or with severe speech and physical

impairments. Grants are worth up to USD 275,000 for a maximum period of two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## End-of-life and palliative care approaches to advanced signs and symptoms (R21 clinical trial optional)

#### **NIH: National Institute of Nursing Research**

This supports the examination of the multi-dimentional foundation, experiences and management of complex, advanced signs and symptoms at the end of life. Grants are worth up to USD 275,000 each

over a maximum period of two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

#### Strategies to provide culturally tailored palliative and end-oflife care for seriously ill American Indian and Alaska Native individuals (R21 clinical trial optional)

#### **NIH: National Institute of Nursing Research**

This supports research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care for American Indian and Alaska Native individuals with advanced illness and their families and communities.

Grants are worth up to USD 275,000 each over a maximum period of two years.

Closing date: 16 Feb 22



## <u>Processing and presentation of non-conventional MHC ligands</u> (R21 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports the determination of antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptiic ligands and of the contribution of these unique antigenic ligands to protective immune responses.

Grants are worth up to USD 275,000 each for a maximum period of two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## <u>Telomeres in wellness and disease – a biobehavioural approach (R21 clinical trial optional)</u>

#### **NIH: National Institute of Nursing Research**

This aims to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioural programmes of research. Grants are

worth up to USD 275,000 each for a maximum period of two years.

Closing date: 16 Feb 22

Link to \*Research Professional

## Molecular and genetic characterisation of inborn errors of immunity (R21 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This aims to advance the experimental validation and functional characterisation of genetic variants in coding or noncoding genomic regions that result in inborn errors of immunity or primary immunodeficiency diseases. The combined budget for direct

costs for the two-year project period may not exceed USD 275,000, with no more than USD 200,000 in any single year.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis and other select endemic fungal infections (R21 clinical trial not allowed)

NIH: National Institute of Allergy and Infectious Diseases



This supports research that contributes to the overall understanding of coccidioidomycosis and other select endemic fungal diseases including histoplasmosis and blastomycosis.

Grants are worth up to USD 275,000 each for a maximum period of two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## Advancing development of rapid fungal diagnostics (R21 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports the development of rapid, sensitive, specific, simple and cost-effective diagnostics for primary healthcare settings. Grants

are worth up to USD 275,000 each over two years.

Closing date: 16 Feb 22

Link to \*Research Professional

## **Exploratory or developmental research grant programme (parent R21 basic experimental studies with humans required)**

#### **NIH: National Eye Institute**

This supports exploratory and developmental research projects in the early and conceptual stages of these projects. Awards are worth up

to USD 275,000 in direct costs for up to two years.

Closing date: 16 Feb 22

Link to \*Research Professional

## Emotion regulation, ageing and mental disorder (R21 clinical trial not allowed)

#### **NIH: National Institute of Neurological Disorders and Stroke**

This supports mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults. Grants are each worth up to USD 275,000 over two years.

Closing date: 16 Feb 22



## **Exploratory/developmental bioengineering research grants** (R21 clinical trial not allowed)

#### **NIH: National Cancer Institute**

This supports the demonstration of feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical or clinical

research, clinical care delivery or accessibility. Direct costs are limited to USD 275,000 over a two-year period.

Closing date: 16 Feb 22

Link to \*Research Professional

# EXTENDED DEADLINE: Accelerating the pace of child health research using existing data from the adolescent brain cognitive development study (R21 clinical trial not allowed)

#### **NIH: National Institute on Drug Abuse**

This supports the analysis of public data to increase knowledge of adolescent health and development.

Grants are worth up to USD 275,000 each for two years.

Closing date: 16 Feb 22

Link to \*Research Professional

#### Biology of bladder cancer (R21 clinical trial optional)

#### **NIH: National Cancer Institute**

This supports research into the biology and underlying molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Grants are worth up to USD 275,000 for two years.

Closing date: 16 Feb 22

Link to \*Research Professional

## Clinical research study planning grant programme (R34 clinical trial not allowed)

#### **NIH: National Eye Institute**

This supports the refinement of a study protocol and procedures and the development of a detailed manual of procedures, as well as preliminary studies to refine study procedures or document

recruitment potential. Grants are worth up to USD 150,000 each per year for up to two years.

Closing date: 16 Feb 22



## Novel RNAs in virology and immune regulation – basic science and therapeutic discovery (R21 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports basic science research in novel biologically active viral or host RNAs involved in virology, including HIV biology, and immune regulation. Grants are worth up to USD 275,000 for two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## Modulating human microbiome function to enhance immune responses against cancer (R21 clinical trial not allowed)

#### **NIH: National Cancer Institute**

This supports basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumour immune responses, and to identify potential novel molecular targets for cancer

prevention strategies. The grant is worth up to USD 275,000 over two years.

Closing date: 16 Feb 22

Link to \*Research Professional

#### Mechanisms of tolerance (R21/R33 clinical trial required)

#### **National Institute on Alcohol Abuse and Alcoholism**

This supports research on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. Grants are worth up to USD 1.77 million each for up to five years.

Closing date: 16 Feb 22

Link to \*Research Professional

Small research grant programme for the next generation of clinical researchers in Alzheimer's disease and Alzheimer's disease related dementias research – area of focus archiving and leveraging existing data sets for analyses (R03 clinical trial not allowed)

**NIH: National Institute on Aging** 



This supports archiving and leveraging existing data sets for analyses of projects covering a wide array of topics relating to Alzheimer's disease and Alzheimer's disease-related dementias. Grants

are worth up to USD 100,000 per year each for up to two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

# Small research grant programme for the next generation of clinical researchers in AD/ADRD research – area of focus systems biology (R03 clinical trial not allowed)

#### **NIH: National Institute on Aging**

This supports innovative system biology projects in which more scientific insight is needed to improve the prevention, diagnosis, treatment and care for individuals with Alzheimer's disease and related dementias. Grants are worth up to USD 100,000 each per year for up to two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

# Small research grant programme for the next generation of clinical researchers in AD/ADRD research – area of focus basic science (R03 clinical trials not allowed)

#### **NIH: National Institute on Aging**

This supports innovative projects focused on basic science approaches to elucidate neurodegenerative mechanisms or pathways of Alzheimer's disease and related dementias. Grants are worth up to

USD 100,000 each per year for up to two years.

Closing date: 16 Feb 22

Link to \*Research Professional

## Catalytic tool and technology development in kidney, urological and haematological diseases (R21 clinical trial not allowed)

#### NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports the development of innovative, enabling tools and technologies in the areas of kidney, urological and haematological

diseases. Grants are worth up to USD 275,000 each for up to two years.

Closing date: 16 Feb 22



## Research on myalgic encephalomyelitis/chronic fatigue syndrome (R21 clinical trials not allowed)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports research to examine the aetiology, diagnosis,

pathophysiology and manifestations

of myalgic

encephalomyelitis/chronic fatigue syndrome in diverse groups and

across the lifespan. Grants are worth up to USD 275,000 each for up to two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## Notice of special interest – small grants for secondary analyses of existing data sets and stored biospecimens

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports projects involving secondary analyses using publicly available National Institute of Child Health and Human Developmentfunded data sets or stored biospecimens.

Closing date: 16 Feb 22

Link to \*Research Professional

## Mood and psychosis symptoms during the menopause transition (R21 clinical trial optional)

#### **NIH: National Institute of Neurological Disorders and Stroke**

This supports research that advances mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition. Awards are worth up to USD 275,000 each for up to two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## NICHD small research grant programme (R03 basic experimental studies with humans required)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development



This supports clinical trials that fall within the institute's mission, and are relevant to normal and abnormal human development. Grants are

worth up to USD 50,000 each in direct costs per year for two years.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

Notice of special interest – use of digital technology and mobile health to improve diagnosis, assessments, interventions, management and outcomes for individuals with down syndrome across the lifespan (R21 clinical trial not allowed)

#### **NIH: National Center for Complementary and Integrative Health**

This supports research investigating digital technology and mobile health tools for children and adults with intellectual and developmental

disabilities. with a focus on Down syndrome.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## <u>Imaging - science track award for research transition (R03 basic experimental studies with humans required)</u>

#### **NIH: National Institute on Drug Abuse**

This facilitates the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programmes, to

enable them to conduct small proof of concept studies. Awards are worth up to USD 150,000 each for a maximum period of one year.

Closing date: 16 Feb 22

**Link to \*Research Professional** 

## Basic research in cancer health disparities (R03 clinical trial not allowed)

#### **NIH: National Cancer Institute**

This supports basic, mechanistic research into the biological and genetic causes of cancer health disparities that can be carried out in a short period of time with limited

resources. Grants are worth up to USD 100,000 over up to two years.

Closing date: 16 Feb 22



## Basic research in cancer health disparities (R21 clinical trial not allowed)

#### **NIH: National Cancer Institute**

This supports basic, mechanistic research into the biological and genetic causes of cancer health disparities that can be carried out in a short period of time with limited resources. Grants are worth up to

USD 550,000 each over up to two years.

Closing date: 16 Feb 22

Link to \*Research Professional

## Regenerative medicine clinical trial planning grant (R34 clinical trials not allowed)

#### **NIH: National Eye Institute**

This supports the preparation of a clinical trial manual of procedures, and procedures necessary for implementing a clinical trial to evaluate interventions or new treatments that restore vision in humans

through regeneration of cells. Awards are worth up to USD 150,000 each in direct costs per year for a maximum of two years.

Closing date: 16 Feb 22

Link to \*Research Professional

## Ethical, legal and social implications small research grant (R03 clinical trial optional)

#### **NIH: National Human Genome Research Institute**

This supports small-scale studies on the ethical, legal and social implications of human genome research. Application budgets are limited to no more than USD 50,000 in direct costs per year. The maximum project period is two years.

Closing date: 17 Feb 22

**Link to \*Research Professional** 

## Ethical, legal and social implications research (R01 clinical trial optional)

#### **NIH: National Human Genome Research Institute**

This supports studies on the ethical, legal and social implications of human genome research.

Application budgets are not limited but need to reflect the actual needs



of the proposed project over up to five years.

Closing date: 17 Feb 22

**Link to \*Research Professional** 

# <u>Ethical, legal and social implications of genomics research – exploratory/developmental research programme (R21 clinical trial optional)</u>

#### **NIH: National Human Genome Research Institute**

This supports studies on the ethical, legal and social implications of human genome research.

Application budgets are limited to

USD 275,000 in direct costs for up to two years.

Closing date: 17 Feb 22

**Link to \*Research Professional** 

#### **Enabling discovery through GEnomics (EDGE)**

#### **National Science Foundation**

This supports the development of innovative tools, technologies, resources and infrastructure that advance biological research focused on the identification of the causal mechanisms connecting genes and

phenotypes. Between 10 and 15 grants are available, each worth up to USD 2 million for four years.

Closing date: 17 Feb 22

**Link to \*Research Professional** 

# Exploratory data science methods and algorithm development in infectious and immune-mediated diseases (R21 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports exploratory research focused on developing innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the infectious or immune-mediated disease research

continuum. Awards are worth up to USD 275,000 each in direct costs over two years.

Closing date: 17 Feb 22



# Enhancement or sustainment of data science tools for infectious and immune-mediated diseases (U24 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports the enhancement or sustainment of high-value data science research software to improve the acquisition, management, analysis, visualisation, and dissemination of data and knowledge across the immunemediated, and infectious-disease

research continuum. Awards are worth up to USD 600,000 each in direct costs per year for up to five years.

Closing date: 17 Feb 22

Link to \*Research Professional

# Early-stage development of data science technologies for infectious and immune-mediated diseases (U01 clinical trial not allowed)

#### NIH: National Institute of Allergy and Infectious Diseases

This supports the development of enabling data science technologies to improve the acquisition, management, analysis, visualisation, and dissemination of data and knowledge for immune-mediated and infectious diseases. Awards are

worth up to USD 300,000 each in direct costs per year for up to three years.

Closing date: 17 Feb 22

Link to \*Research Professional

Age-related macular degeneration (AMD) integrative biology initiative – discovery of AMD pathobiology using patient-derived induced pluripotent stem cell-derived retinal pigment epithelium (U01 clinical trial not allowed)

#### **NIH: National Eye Institute**

This supports collaborative studies of a unique resource of patient-derived induced pluripotent stem cell lines generated by the National Eye Institute's age-related macular degeneration integrative biology initiative. Up to twelve awards,

worth up to USD 250,000 each in direct costs per year for a maximum of three years, are available.

Closing date: 17 Feb 22



## <u>Translational neural devices programme (UG3/UH3 clinical trial required)</u>

#### NIH: National Institute of Neurological Disorders and Stroke

This supports translational activities and small clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Application budgets are not limited but need to reflect the actual

needs of the proposed project. The maximum project period is five years.

Closing date: 18 Feb 22

Link to \*Research Professional

#### <u>Comparative effectiveness research in clinical neurosciences</u> (UG3/UH3 clinical trial not allowed)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports prospective observational comparative effectiveness research evaluating preventive strategies, diagnostic approaches or interventions including drugs, biologics and devices or surgical, behavioural and

rehabilitation therapies. The maximum project period is seven years.

Closing date: 18 Feb 22

**Link to \*Research Professional** 

#### **Blueprint MedTech translator (UG3/UH3 clinical trial optional)**

#### NIH: National Institute of Neurological Disorders and Stroke

This supports investigators pursuing translational activities and clinical feasibility studies to advance the development of therapeutic or diagnostic devices for disorders that

affect the nervous or neuromuscular systems.

Closing date: 18 Feb 22

**Link to \*Research Professional** 

## Advancing Group A Streptococcus vaccine discovery (R01 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports discovery and design of novel Group A Streptococcus (GAS) vaccine candidates and their advancement into preclinical evaluation for broad protection against GAS infections. Application budgets are limited to less than USD 500,000 in direct costs per year and need to reflect the actual needs of



the proposed project. The maximum project period is five years.

Closing date: 18 Feb 22

Link to \*Research Professional

## Fertility status as a marker for overall health (R01 clinical trial optional)

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research exploring the premise that fertility status can be a marker for overall health. The

maximum project period is five years.

Closing date: 19 Feb 22

**Link to \*Research Professional** 

## Fertility status as a marker for overall health (R21 clinical trial not allowed)

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research exploring the premise that fertility status can be a marker for overall health. Grants are

worth up to USD 275,000 for up to two years.

Closing date: 19 Feb 22

Link to \*Research Professional

## Novel assays to address translational gaps in treatment development (UG3/UH3 clinical trial optional)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports proof-of-concept studies to identify neurophysiological measures as potential assays for treatment development research. Application budgets are not limited but need to reflect the actual needs of the proposed project. Funding is for a maximum period of four years.

Closing date: 21 Feb 22



#### <u>Innovation grants to nurture initial translational efforts –</u> <u>neurotherapeutic agent characterisation and in vivo efficacy</u> <u>studies (R61/R33 clinical trial not allowed)</u>

#### NIH: National Institute of Neurological Disorders and Stroke

This supports pharmacodynamic, pharmacokinetic and in vivo efficacy studies to demonstrate that proposed therapeutic agents have sufficient biological activity to warrant further development to treat neurological or neuromuscular

disorders. Grants are worth up to USD 750,000 each over a maximum of three years.

Closing date: 22 Feb 22

**Link to \*Research Professional** 

# <u>Innovation grants to nurture initial translational efforts – assay development and neurotherapeutic agent identification (R61/R33 clinical trial not allowed)</u>

#### NIH: National Institute of Neurological Disorders and Stroke

This supports research that develops in vitro or ex vivo assays and conducts iterative screening efforts to identify and characterise potential therapeutic agents for neurological or neuromuscular disorders. Grants are worth up to USD 750,000 each over a maximum of three years.

Closing date: 22 Feb 22

Link to \*Research Professional

Innovation grants to nurture initial translational efforts – development and validation of model systems to facilitate neurotherapeutic discovery (R61/R33 clinical trials not allowed)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports the development and validation of animal models and human or animal tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular

disorder. Grants are worth up to USD 750,000 each over a maximum of three years.

Closing date: 22 Feb 22



## NCI clinical and translational exploratory or developmental studies (R21 clinical trial optional)

#### **NIH: National Cancer Institute**

This supports the development of new exploratory cancer research. Grants are worth up to USD 275,000 for up to two years.

Closing date: 22 Feb 22

**Link to \*Research Professional** 

#### <u>Discovery of biomarkers and biomarker signatures for</u> <u>neurological and neuromuscular disorders (R61/R33 clinical</u> <u>trial optional)</u>

#### NIH: National Institute of Neurological Disorders and Stroke

This promotes the discovery or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Application

budgets are not limited but need to reflect the actual needs of the proposed project.

Closing date: 22 Feb 22

**Link to \*Research Professional** 

## Innovative biospecimen science technologies for basic and clinical cancer research (R61 clinical trial not allowed)

#### **NIH: National Cancer Institute**

This supports exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. The

NCI expects to fund four awards, worth up to USD 150,000 per year each, for up to three years.

Closing date: 22 Feb 22

Link to \*Research Professional

# Secondary analysis of existing datasets in heart, lung and blood diseases and sleep disorders (R21 clinical trial not allowed)

#### **NIH: National Heart, Lung and Blood Institute**

This enables the use of existing human datasets for well-focused

secondary analyses to investigate novel scientific ideas or new models,



systems, tools, methods or technologies that have the potential for significant impact on biomedical or biobehavioural research in areas relevant to the institute's mission. Grants are worth up to USD 150,000 each for a two year period.

Closing date: 26 Feb 22

Link to \*Research Professional

## <u>Laboratories to optimise digital health (R01 clinical trial</u> required)

#### NIH: National Institute of Neurological Disorders and Stroke

This supports research to test strategies to increase the reach, efficiency, effectiveness and quality of digital mental health interventions which may impact mental health outcomes, including suicide behaviours and serious mental illness. The maximum project period is four years.

Closing date: 01 Mar 22

**Link to \*Research Professional** 

## <u>Transformative nucleic acid sequencing technology innovation</u> and early development (R21 clinical trial not allowed)

#### NIH: National Human Genome Research Institute

This supports research aimed at innovating and developing the early stages of novel technologies that will enable greater than a one order of magnitude improvement in DNA sequencing, and methods for direct sequencing of the diversity of entire

RNA molecules. Awards are worth up to USD 400,000 each per year in direct costs for a maximum of three years.

Closing date: 01 Mar 22

**Link to \*Research Professional** 

## <u>Transformative nucleic acid sequencing technology innovation</u> and early development (R01 clinical trial not allowed)

#### **NIH: National Human Genome Research Institute**

This supports the innovation and development of the early stages of novel technologies that will enable greater than a one order of magnitude improvement in DNA sequencing and methods for direct sequencing of the diversity of entire

RNA molecules. Grants are worth up to USD 700,000 each per year for a maximum period of four years.

Closing date: 01 Mar 22



## Transformative nucleic acid sequencing technology innovation and early development (R21 clinical trial not allowed)

#### NIH: National Human Genome Research Institute

This supports the innovation and development of the early stages of novel technologies that will enable greater than a one order of magnitude improvement in DNA sequencing and methods for direct sequencing of the diversity of entire

RNA molecules. Grants are worth up to USD 400,000 each over a maximum period of three years.

Closing date: 01 Mar 22

**Link to \*Research Professional** 

## <u>Pilot effectiveness trials of interventions for preschoolers with</u> <u>ADHD (R34 clinical trial required)</u>

#### **NIH: National Institute of Neurological Disorders and Stroke**

This supports pilot projects aimed at evaluating the preliminary effectiveness of interventions targeting preschool ADHD symptoms and impairments. Up to five awards are available, each

worth up to USD 450,000 for three years.

Closing date: 01 Mar 22

**Link to \*Research Professional** 

## Method to extend research in time award extension request (type 4 clinical trial optional)

#### **NIH: National Cancer Institute**

This provides extended grant support to early stage investigators who qualify for conversion based on receiving a percentile within the NCI payline for established investigators on their R01 applications. Available

grant budgets depend on the parent award, and may be provided for up to two years.

Closing date: 01 Mar 22

Link to \*Research Professional

#### Animal genomics programme (U01 clinical trial not allowed)

#### **NIH: National Institute on Drug Abuse**

This supports the discovery of genetic, genomic, and molecular genetic and epigenetic variants that underlie phenotypes associated with addictive behaviours or

vulnerabilities, behaviours associated with substance use disorder, and comorbidities that demonstrate genetic correlations with such phenotypes and



behaviours. Grants are tenable for up to five years.

Closing date: 02 Mar 22

**Link to \*Research Professional** 

# <u>Understanding the role of bilingualism in cognitive</u> <u>reserve/resilience in ageing and AD/ADRD (R01 clinical trial</u> optional)

#### **NIH: National Institute on Aging**

This supports research studying the role of bilingualism as it relates to cognitive reserve/resilience in healthy ageing and in Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 03 Mar 22

**Link to \*Research Professional** 

## <u>Dyadic interpersonal processes and biopsychosocial outcomes</u> (R01 basic experimental studies with humans)

#### **NIH: National Institutes of Health**

This supports basic and methodological research projects that illuminate or measure independent and interdependent health-related effects within dyads across relationships and settings. Application budgets are not limited

but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 05 Mar 22

**Link to \*Research Professional** 

## Modular R01s in cancer control and population sciences (R01 clinical trial optional)

#### **NIH: National Cancer Institute**

This supports research in cancer control and population sciences. Grants are worth up to USD 250,000

each per year over a maximum period of five years.

Closing date: 07 Mar 22



#### **Cutting-edge basic research awards (R21 clinical trial optional)**

#### **NIH: National Institute on Drug Abuse**

This supports high-risk and potentially high-impact research that is underrepresented or not included in National Institute Drug Abuse's current portfolio that has the potential to transform substance

abuse disorder research. Grants are worth up to USD 275,000 for a maximum period of two years.

Closing date: 08 Mar 22

**Link to \*Research Professional** 

## Integrated preclinical and clinical AIDS vaccine development programme (U19 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This aims to facilitate the translation of vaccine candidates for HIV-1 into early clinical testing. Grants are

worth up to USD 3 million each for up to five years.

Closing date: 09 Mar 22

Link to \*Research Professional

## Autoantigens and neoantigens function in the aetiology and pathophysiology of type 1 diabetes (R01 clinical trial optional)

#### NIH: National Institute of Diabetes and Digestive and Kidney Diseases

This supports research aimed at the characterisation of the function of neoepitopes and neoantigens in type 1 diabetes. Awards are worth up to

USD 500,000 each per year in direct costs for up to five years.

Closing date: 09 Mar 22

Link to \*Research Professional

# Explainable artificial intelligence for decoding and modulating neural circuit activity linked to behaviour (R01 clinical trial optional)

#### **NIH: National Institute of Neurological Disorders and Stroke**

This supports research in the field of explainable artificial intelligence applied to neuroscientific questions of encoding, decoding and modulation of neural circuits linked to behaviour. The maximum project period is five years.

Closing date: 10 Mar 22



## <u>Small-cell lung cancer consortium – biology, therapy and</u> resistance (U01 clinical trial not allowed)

#### **NIH: National Cancer Institute**

This supports projects to joint to small-cell lung cancer consortium. Grants are worth up to USD 450,000 per year for up to five years.

Closing date: 11 Mar 22

**Link to \*Research Professional** 

# Clinical relevance of the linkage between environmental toxicant exposures and Alzheimer's disease and related dementias (R01 clinical trial not allowed)

#### **NIH: National Institute of Neurological Disorders and Stroke**

This supports mechanistic and early translational research focused on indepth examination of the potential interactions of environmental toxins with genetic and non-genetic molecular targets known to influence Alzheimer's disease and Alzheimer's disease related

dementias. Approximately five awards will be available, each worth up to USD 500,000 per year for up to five years.

Closing date: 11 Mar 22

**Link to \*Research Professional** 

# Extracellular RNA carrier subclasses in processes relevant to substance use disorders or HIV infection (R21 clinical trial not allowed)

#### **NIH: National Institute on Drug Abuse**

This supports research that investigates the roles of extracellular ribonucleid acid carrier subclasses in biological processes relevant to substance use disorders or HIV infection. Awards are worth up to

USD 275,000 each for up to two years.

Closing date: 15 Mar 22

**Link to \*Research Professional** 

## HIV vaccine research and design programme (P01 clinical trial not allowed)

**NIH: National Institute of Allergy and Infectious Diseases** 



This supports multi-component, multidisciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research. Grants are worth up to USD 2.5 million each per year for up to five years.

Closing date: 15 Mar 22

**Link to \*Research Professional** 

#### Research on bat immunology (R21 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports research to characterise cellular and molecular constituents of the bat immune system and to understand protective innate and adaptive immune mechanisms in bats. Grants are

worth USD 275,000 over two years, with a maximum of USD 200,000 per year.

Closing date: 15 Mar 22

**Link to \*Research Professional** 

## RePORT international coordinating centre (RICC) (U01 clinical trial not allowed)

#### **NIH: National Institute of Allergy and Infectious Diseases**

This supports the development of a regional prospective observational research in tuberculosis international coordinating center for the national networks, whose mission is to advance regional and international TB and TB and HIV science, strengthen TB and HIV

research capacity and infrastructure, and foster research collaboration.
One award worth up to USD four million is available.

Closing date: 17 Mar 22

Link to \*Research Professional

#### **Early-career grants**

#### **Human Frontier Science Program**

These support teams of early-career researchers working on innovative approaches to understanding complex mechanisms of living organisms. Grant size depends on the size of the team and grants are

worth up to USD 465,000 per year over three years.

Closing date: 18 Mar 22 (Forecast)
Link to \*Research Professional



## Behavioural and integrative treatment development programme (R01 clinical trial optional)

#### **NIH: National Institute on Drug Abuse**

This supports research on the development and testing of behavioural and integrative treatments for drug and alcohol use, abuse and dependence. The

maximum project period is five years.

Closing date: 23 Mar 22

Link to \*Research Professional

## Behavioural and integrative treatment development programme (R34 clinical trial optional)

#### **NIH: National Institute on Drug Abuse**

This supports research on the development and testing of behavioural and integrative treatments for drug and alcohol use, abuse and dependence. Application

budgets are limited to USD 450,000 over three years.

Closing date: 23 Mar 22

**Link to \*Research Professional** 

#### National Center for Medical Rehabilitation Research earlycareer research award (R03 clinical trial optional)

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports both basic and clinical research from rehabilitation scientists who are establishing independent research careers.

Grants are worth up to USD 200,000 each for up to two years.

Closing date: 30 Mar 22

Link to \*Research Professional

## Elucidating the role of nutrition in care and development of preterm infants (R01 clinical trial optional)

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research addressing priority gaps in understanding the role of nutrition in the care and development of preterm infants.

Grants are worth up to USD 499,999 each per year for up to four years.

Closing date: 30 Mar 22



## Promoting reproductive health for adolescents and adults with disabilities (R01 clinical trial optional)

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research that addresses gaps in our understanding of best practices for promoting reproductive health across the transition from adolescence to adulthood for persons with disabilities. Application budgets are

not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 30 Mar 22

**Link to \*Research Professional** 

## Promoting reproductive health for adolescents and adults with disabilities (R01 clinical trial optional)

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports research that addresses gaps in our understanding of best practices for promoting reproductive health across the transition from adolescence to adulthood for persons with disabilities. There is a budget of USD

2.1 million to fund three or four awards with a maximum project period of five years.

Closing date: 30 Mar 22

Link to \*Research Professional

## Home and community-based physical activity interventions to improve the health of wheelchair users (R01 clinical trial required)

### NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

This supports the development, adaptation and testing of physical activity interventions for individuals who use wheelchairs due to physical disability in order to safely prevent or reverse chronic conditions associated with low physical activity

such as diabetes, cardiovascular disease, and obesity. A budget of USD 1.5 million is available to fund three awards for up to five years.

Closing date: 30 Mar 22



# Notice of special interest – administrative supplements and urgent competitive revisions for research on the 2019 novel coronavirus

#### **NIH: National Institute on Drug Abuse**

This supports research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders and HIV-affected populations. Grants are worth up to

USD 100,000 each per year for maximum period of two years.

Closing date: 31 Mar 22